



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/00, 9/64, A01K 67/027	A1	(11) International Publication Number: WO 97/20043 (43) International Publication Date: 5 June 1997 (05.06.97)
(21) International Application Number: PCT/US96/18866 (22) International Filing Date: 26 November 1996 (26.11.96) (30) Priority Data: 08/565,074 30 November 1995 (30.11.95) US 60/019,692 13 June 1996 (13.06.96) US (71) Applicants: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US). PPL THERAPEUTICS [GB/GB]; Roslin, Edinburgh, Midlothian EH25 9PP (GB). (72) Inventors: GARNER, Ian; 13 Lismore Avenue, Edinburgh EH8 7DW (GB). COTTINGHAM, Ian; 9 Buckstone Row/Fairmilehead, Edinburgh EH10 6TW (GB). TEMPERLEY, Simon, M.; 12/4 Whitehorse Close, 27 Canon Gate, Edinburgh EH8 8BU (GB). FOSTER, Donald, C.; 3002 N.E. 181st Street, Seattle, WA 98155 (US). SPRECHER, Cindy, A.; 8207 39th Avenue N.E., Seattle, WA 98115 (US). PRUNKARD, Donna, E.; 1463 N.E. 92nd Street, Seattle, WA 98117 (US). (74) Agent: SAWISLAK, Deborah, A.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PROTEIN C PRODUCTION IN TRANSGENIC ANIMALS (57) Abstract <p>Methods for producing protein C in transgenic non-human mammals are disclosed. The protein C is modified at the two-chain cleavage site between the light and heavy chains of protein C from Lys-Arg to R₁-R₂-R₃-R₄ where R₁ through R₄ are individually Arg or Lys. DNA segments encoding modified protein C are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing protein C expressed from the introduced DNA segments. The protein C expressed from the introduced DNA segments has anticoagulant activity when activated. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous protein C are also disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Vietnam

DESCRIPTION

5 Protein C Production in Transgenic Animals

BACKGROUND OF THE INVENTION

Protein C in its activated form plays an important role in regulating blood coagulation. The
10 activated protein C, a serine protease, inactivates coagulation Factors Va and VIIIa by limited proteolysis. The coagulation cascade initiated by tissue injury, for example, is prevented from proceeding in an unimpeded chain-reaction beyond the area of injury by activated
15 protein C.

Protein C is synthesized in the liver as a single chain precursor polypeptide which is subsequently processed to a light chain of about 155 amino acids ($M_r = 21,000$) and a heavy chain of 262 amino acids ($M_r = 40,000$).
20 The heavy and light chains circulate in the blood as a two-chain inactive protein, or zymogen, held together by a disulfide bond. When a 12 amino acid residue peptide is cleaved from the amino terminus of the heavy chain portion of the zymogen in a reaction mediated by thrombin, the
25 protein becomes activated. The N-terminal portion of the light chain contains nine γ -carboxyglutamic acid (Gla) residues that are required for the calcium-dependent membrane binding and activation of the molecule. Another blood protein, referred to as "protein S", is believed to
30 accelerate the protein C-catalyzed proteolysis of Factor Va.

Protein C has also been implicated in the action of tissue-type plasminogen activator (Kisiel et al., Behring Inst. Mitt. 73:29-42, 1983). Infusion of bovine
35 activated protein C (APC) into dogs results in increased plasminogen activator activity (Comp et al., J. Clin. Invest. 68:1221-1228, 1981). Other studies (Sakata et

al., Proc. Natl. Acad. Sci. USA 82:1121-1125, 1985) have shown that addition of APC to cultured endothelial cells leads to a rapid, dose-dependent increase in fibrinolytic activity in the conditioned media, reflecting increases in the activity of both urokinase-related and tissue-type plasminogen activators. APC treatment also results in a dose-dependent decrease in anti-activator activity. In addition, studies with monoclonal antibodies against endogenous APC (Snow et al., FASEB Abstracts, 1988) implicate APC in maintaining patency of arteries during fibrinolysis and limiting the extent of tissue infarct.

Experimental evidence indicates that protein C may be clinically useful in the treatment of thrombosis. Several studies with baboon models of thrombosis have indicated that activated protein C in low doses will be effective in prevention of fibrin deposition, platelet deposition and loss of circulation (Gruber et al., Hemostasis and Thrombosis 374a: abstract 1512, 1988; Widrow et al., Fibrinolysis 2 suppl. 1: abstract 7, 1988; Griffin et al., Thromb. Haemostasis 62: abstract 1512, 1989).

In addition, exogenous activated protein C has been shown to prevent the coagulopathic and lethal effects of gram negative septicemia (Taylor et al., J. Clin. Invest. 19:918-925, 1987). Data obtained from studies with baboons suggest that activated protein C plays a natural role in protecting against septicemia.

Until recently, protein C was purified from clotting factor concentrates (Marlar et al., Blood 59:1067-1072, 1982) or from plasma (Kisiel, J. Clin. Invest. 64:761-769, 1979) and activated in vitro. However, the possibility that the resulting product could be contaminated with such infectious agents as hepatitis virus, cytomegalovirus, or human immunodeficiency virus (HIV) make the process unfavorable.

While expression of protein C through recombinant means has been theoretically possible as the

genes for both human and bovine protein C are known (Foster et al., Proc. Natl. Acad. Sci. USA 82:4673-4677, 1985; Foster et al., Proc. Natl. Acad. Sci. USA 81:4766-4770, 1984 and U.S. Patent 4,775,624), it has been met
5 with limited success. Expression of some vitamin K-dependent proteins, such as protein C in cultured cells, has not produced protein C that has been at both commercially valuable levels and biologically functional when activated (i.e. had anticoagulant activity (Grinnell
10 et al., in Bruley and Drohn, eds., Protein C and Related Anticoagulants:29-63, Gulf Publishing, Houston, TX and Grinnell et al., Bio/Technol. 5:1189-1192, 1987)). Transgenic expression of protein C has yielded somewhat higher levels of expression, but the recombinant protein's
15 anticoagulant activity has still remained low, with less than 50% of the material having biological activity (Velandar et al., Proc. Natl. Acad. Sci. USA 89:12003-12007, 1992). Therefore, there remains a need for producing protein C that is both expressed at high levels
20 and has therapeutic value.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide methods for producing protein C in transgenic
25 animals. It is a further object to provide transgenic animals that express human protein C in a mammary gland.

Within one aspect, the present invention provides methods for producing protein C in a transgenic animal comprising (a) providing a DNA construct comprising
30 a first DNA segment encoding a secretion signal and a protein C propeptide operably linked to a second DNA segment encoding protein C, wherein the encoded protein C comprises a two-chain cleavage site modified from Lys-Arg to R₁-R₂-R₃-R₄, and wherein each of R₁-R₄ is individually
35 Lys or Arg, and wherein said first and second segments are operably linked to additional DNA segments required for expression of the protein C DNA in a lactating mammary

gland of a host female animal; (b) introducing said DNA construct into a fertilized egg of a non-human mammalian species; (c) inserting said egg into an oviduct or uterus of a female of said species to obtain offspring carrying said DNA construct; (d) breeding said offspring to produce female progeny that express said first and second DNA segments and produce milk containing protein C encoded by said second segment, wherein said protein has anticoagulant activity upon activation; (e) collecting milk from said female progeny; and (f) recovering the protein C from the milk. In one embodiment, R₁-R₂-R₃-R₄ is Arg-Arg-Lys-Arg (SEQ ID NO: 20). In another embodiment, the method further comprises the step of activating the protein C. In another embodiment, the non-human mammalian species is selected from sheep, rabbits, cattle and goats. In another embodiment each of the first and second DNA segments comprises an intron. In another embodiment, the second DNA segment comprises a DNA sequence of nucleotides as shown in SEQ ID NO: 1 or SEQ ID NO:3. In another embodiment, the additional DNA segments comprise a transcriptional promoter selected from the group consisting of casein, β -lactoglobulin, α -lactoglobulin, α -lactalbumin and whey acidic protein gene promoters.

In another aspect, the present invention provides a transgenic non-human female mammal that produces recoverable amounts of human protein C in its milk, wherein at least 90% of the human protein C in the milk is two-chain protein C.

In another aspect, the present invention provides a process for producing a transgenic offspring of a mammal comprising the steps of (a) providing a DNA construct comprising a first DNA segment encoding a secretion signal and a protein C propeptide operably linked to a second DNA segment encoding protein C, wherein the encoded protein C comprises a two-chain cleavage site modified from Lys-Arg to R₁-R₂-R₃-R₄, and wherein each of

R_1 - R_4 is individually Lys or Arg, and wherein said first and second segments are operably linked to additional DNA segments required for expression of the protein C DNA in a lactating mammary gland of a host female animal; (b) 5 introducing said DNA construct into a fertilized egg of a non-human mammalian species; and (c) inserting said egg into an oviduct or uterus of a female of said species to obtain offspring carrying said DNA construct.

Within another aspect, the present invention 10 provides non-human mammals produced according to the process for producing a transgenic offspring of a mammal comprising the steps of (a) providing a DNA construct comprising a first DNA segment encoding a secretion signal and a protein C propeptide operably linked to a second DNA 15 segment encoding protein C, wherein the encoded protein C comprises a two-chain cleavage site modified from Lys-Arg to R_1 - R_2 - R_3 - R_4 , and wherein each of R_1 - R_4 is individually Lys or Arg, and wherein said first and second segments are operably linked to additional DNA segments required for 20 expression of the protein C DNA in a lactating mammary gland of a host female animal; (b) introducing said DNA construct into a fertilized egg of a non-human mammalian species; and (c) inserting said egg into an oviduct or uterus of a female of said species to obtain offspring 25 carrying said DNA construct.

In another aspect, the present invention provides a non-human mammalian embryo containing in its nucleus a heterologous DNA segment encoding protein C, wherein the encoded protein C comprises a two-chain 30 cleavage site modified from Lys-Arg to R_1 - R_2 - R_3 - R_4 , and wherein each of R_1 - R_4 is individually Lys or Arg.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates analysis of plasma-derived 35 and transgenic protein C run under non-reducing and reducing conditions. Lane 1 is plasma-derived protein C

and lane 2 is transgenic protein C from the milk of sheep 30851.

Figure 2 illustrates sequencing of protein C from sheep line 30851. The initial yields were 5 prosequence=9 pmol, light chain=563 pmol and heavy chain=565 pmol.

Figure 3 illustrates clotting activity of transgenic protein C compared to plasma-derived protein C.

10 DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention in detail, it will be helpful to define certain terms used herein:

As used herein, the term "biologically active" is used to denote protein C that is characterized by its 15 anticoagulant and fibrinolytic properties. Protein C, when activated, inactivates factor Va and factor VIIIa in the presence of phospholipid and calcium. Activated protein C also enhances fibrinolysis, an effect believed to be mediated by the lowering of the levels of 20 plasminogen activator inhibitors. As stated previously, two-chain protein C is activated upon cleavage of a 12 amino acid peptide from the amino terminus of the heavy chain portion of the zymogen.

The term "egg" is used to denote an unfertilized 25 ovum, a fertilized ovum prior to fusion of the pronuclei or an early stage embryo (fertilized ovum with fused pronuclei).

A "female mammal that produces milk containing biologically active protein C" is one that, following 30 pregnancy and delivery, produces, during the lactation period, milk containing recoverable amounts of protein C that can be activated to be biologically active. Those skilled in the art will recognized that such animals will naturally produce milk, and therefore the protein C, 35 discontinuously.

The term "progeny" is used in its usual sense to include offspring and descendants.

The term "heterologous" is used to denote genetic material originating from a different species than that into which it has been introduced, or a protein produced from such genetic material.

5 Within the present invention, transgenic animal technology is employed to produce protein C within a mammary gland of a host female mammal. Expression in the mammary gland and subsequent secretion of the protein of interest into the milk overcomes many difficulties
10 encountered in isolating proteins from other sources. Milk is readily collected, available in large quantities, and well characterized biochemically. Furthermore, the major milk proteins are present in milk at high concentrations (from about 1 to 16 g/l).

15 From a commercial point of view, it is clearly preferable to use as the host a species that has a large milk yield. While smaller animals such as mice and rats can be used (and are preferred at the proof-of-concept stage), within the present invention it is preferred to
20 use livestock mammals including sheep and cattle. Sheep are particularly preferred due to such factors as the previous history of transgenesis in this species, milk yield, generation time, cost and the ready availability of equipment for collecting sheep milk. It is generally
25 desirable to select a breed of host animal that has been bred for dairy use, such as East Friesland sheep, or to introduce dairy stock by breeding of the transgenic line at a later date. In any event, animals of known, good health status should be used.

30 Cloned DNA sequences encoding human protein C have been described (Foster and Davie, Proc. Natl. Acad. Sci. USA 81:4766-4770, 1984; Foster et al., Proc. Natl. Acad. USA 82:4673-4677, 1985; and Bang et al., U.S. Patent 4,755,624, each incorporated herein by reference).
35 Complementary cDNAs encoding protein C can be obtained from libraries prepared from liver cells of various mammalian species according to standard laboratory

procedures. DNAs from other species, such as the protein C encoded by rats, pigs, sheep, cows and primates can be used and can be identified using probes from human cDNA.

In a preferred embodiment, human genomic DNAs
5 encoding protein C are used. The human protein C gene is composed of nine exons ranging in size from 25 to 885 nucleotides, and seven introns ranging in size from 92 to 2668 nucleotides (U.S. Patent 4,959,318, incorporated herein by reference). The first exon is non-coding and
10 referred to as exon 0. Exon I and a portion of exon II code for the 42 amino acid signal sequence and propeptide (i.e., pre-propeptide). The remaining portion of exon II, exon III, exon IV, exon V and a portion of exon VI code for the light chain of protein C. The remaining portion
15 of exon VI, exon VII and exon VIII code for the heavy chain of protein C. A representative human genomic DNA sequence and corresponding amino acid sequence are shown in SEQ ID NOS: 1 and 2, respectively. A representative human protein C cDNA sequence and corresponding amino acid
20 sequences are shown in SEQ ID NO: 3 and 4, respectively.

Those skilled in the art will recognize that naturally occurring allelic variants of these sequences will exist; that additional variants can be generated by amino acid substitution, deletion, or insertion; and that
25 such variants are useful within the present invention. In general, it is preferred that any engineered variants comprise only a limited number of amino acid substitutions, deletions, or insertions, and that any substitutions are conservative. Thus, it is preferred to
30 produce protein C polypeptides that are at least 90%, and more preferably at least 95% or more identical in sequence to the corresponding native protein.

Within the present invention, the proteolytic processing involved in the maturation of recombinant
35 protein C from single chain form to the two-chain form (i.e., cleaved between the light chain and the heavy chain) has been enhanced by modifying the amino acid

sequence around the two-chain cleavage site. In the normal situation, endoproteolytic cleavage of the precursor molecule at the Arg₁₅₇-Asp₁₅₈ bond and the removal of the dipeptide Lys₁₅₆-Arg₁₅₇ by a carboxypeptidase activity generate the light and heavy chains of protein C prior to secretion. Expression of protein C with the native (Lys-Arg) two-chain cleavage site produces protein C that may contain up to 40% or more uncleaved, single-chain protein C (Grinnel et al., in Protein C and Related Anticoagulants, eds., Bruley and Drohan, Gulf, Houston, pp. 29-63, 1990; Suttie, Thromb. Res. 44:129-134, 1986 and Yan et al., Trends Biochem. Sci. 14:264-268, 1989). The single-chain form of protein C may not be able to be activated. The cleavage site may be in the form of the amino acid sequence R₁-R₂-R₃-R₄, wherein each of R₁ through R₄ is individually lysine (Lys) or arginine (Arg). Particularly preferred sequences include Arg-Arg-Lys-Arg (SEQ ID NO: 20) and Lys-Arg-Lys-Arg (SEQ ID NO: 21).

In a preferred embodiment, the present invention provides for recoverable amounts of human protein C in the milk of a non-human mammal, where at least 90%, preferably at least 95%, of the human protein C is two-chain protein C.

To obtain expression in the mammary gland, a transcription promoter from a milk protein gene is used. Milk protein genes include those genes encoding caseins, beta-lactoglobulin (BLG), α -lactalbumin, and whey acidic protein. The beta-lactoglobulin promoter is preferred. In the case of the ovine beta-lactoglobulin gene, a region of at least the proximal 406 bp of 5' flanking sequence of the ovine BLG gene (contained within nucleotides 3844 to 4257 of SEQ ID NO: 5) will generally be used. Larger portions of the 5' flanking sequence, up to about 5 kb, are preferred. A larger DNA segment encompassing the 5' flanking promoter region and the region encoding the 5' non-coding portion of the beta-lactoglobulin gene

(contained within nucleotides 1 to 4257 of SEQ ID NO: 5) is particularly preferred. See Whitelaw et al., Biochem J. 286: 31-39, 1992. Similar fragments of promoter DNA from other species are also suitable.

5 Other regions of the beta-lactoglobulin gene may also be incorporated in constructs, as may genomic regions of the gene to be expressed. It is generally accepted in the art that constructs lacking introns, for example, express poorly in the transgenic lactating mammary gland
10 in comparison with those constructs that contain introns (see Brinster et al., Proc. Natl. Acad. Sci. USA 85: 836-840, 1988; Palmiter et al., Proc. Natl. Acad. Sci. USA 88: 478-482, 1991; Whitelaw et al., Transgenic Res. 1: 3-13, 1991; WO 89/01343; WO 91/02318). In this regard, it is
15 generally preferred, where possible, to use genomic sequences containing all or some of the native introns of a gene encoding protein C. Within certain embodiments of the invention, the further inclusion of at least some introns from the beta-lactoglobulin gene is preferred.
20 One such region is a DNA segment which provides for intron splicing and RNA polyadenylation from the 3' non-coding region of the ovine beta-lactoglobulin gene. When substituted for the natural 3' non-coding sequences of a gene, this ovine beta-lactoglobulin segment can both
25 enhance and stabilize expression levels of the protein C.

For expression of protein C, DNA segments encoding protein C are operably linked to additional DNA segments required for their expression to produce expression units. One such additional segment is the
30 above-mentioned milk protein gene promoter. Sequences allowing for termination of transcription and polyadenylation of mRNA may also be incorporated. Such sequences are well known in the art, for example, one such termination sequence is the "upstream mouse sequence"
35 (McGeady et al., DNA 5:289-298, 1986). The expression units will further include a DNA segment encoding a secretion signal operably linked to the segment encoding

the protein C polypeptide chain. The secretion signal may be a native protein C secretion signal or may be that of another protein, such as a milk protein. The term "secretion signal" is used herein to denote that portion of a protein that directs it through the secretory pathway of a cell to the outside. Secretion signals are most commonly found at the amino termini of proteins. See, for example, von Heinje, Nuc. Acids Res. 14: 4683-4690, 1986; and Meade et al., U.S. Patent No. 4,873,316, which are incorporated herein by reference.

Construction of expression units is conveniently carried out by inserting a protein C sequence into a plasmid or phage vector containing the additional DNA segments, although the expression unit may be constructed by essentially any sequence of ligations. It is particularly convenient to provide a vector containing a DNA segment encoding a milk protein and to replace the coding sequence for the milk protein with that of a protein C (including a secretion signal), thereby creating a gene fusion that includes the expression control sequences of the milk protein gene. In any event, cloning of the expression units in plasmids or other vectors facilitates the amplification of the protein C sequences. Amplification is conveniently carried out in bacterial (e.g. *E. coli*) host cells, thus the vectors will typically include an origin of replication and a selectable marker functional in bacterial host cells.

The expression unit is then introduced into fertilized eggs (including early-stage embryos) of the chosen host species. Introduction of heterologous DNA can be accomplished by one of several routes, including pronuclear microinjection (e.g. U.S. Patent No. 4,873,191), retroviral infection (Jaenisch, Science 240: 1468-1474, 1988) or site-directed integration using embryonic stem (ES) cells (reviewed by Bradley et al., Bio/Technology 10: 534-539, 1992). The eggs are then implanted into the oviducts or uteri of pseudopregnant

females and allowed to develop to term. Offspring carrying the introduced DNA in their germ line can pass the DNA on to their progeny in the normal, Mendelian fashion, allowing the development of transgenic herds.

5 General procedures for producing transgenic animals are known in the art. See, for example, Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, 1986; Simons et al., Bio/Technology 6: 179-183, 1988; Wall et al., Biol.
10 Reprod. 32: 645-651, 1985; Buhler et al., Bio/Technology 8: 140-143, 1990; Ebert et al., Bio/Technology 9: 835-838, 1991; Krimpenfort et al., Bio/Technology 9: 844-847, 1991; Wall et al., J. Cell. Biochem. 49: 113-120, 1992; and WIPO publications WO 88/00239, WO 90/05188, WO 92/11757; and GB
15 87/00458, which are incorporated herein by reference. Techniques for introducing foreign DNA sequences into mammals and their germ cells were originally developed in the mouse. See, e.g., Gordon et al., Proc. Natl. Acad. Sci. USA 77: 7380-7384, 1980; Gordon and Ruddle, Science
20 214: 1244-1246, 1981; Palmiter and Brinster, Cell 41: 343-345, 1985; Brinster et al., Proc. Natl. Acad. Sci. USA 82: 4438-4442, 1985; and Hogan et al. (ibid.). These techniques were subsequently adapted for use with larger
25 animals, including livestock species (see e.g., WIPO publications WO 88/00239, WO 90/05188, and WO 92/11757; and Simons et al., Bio/Technology 6: 179-183, 1988). To summarize, in the most efficient route used to date in the generation of transgenic mice or livestock, several
30 hundred linear molecules of the DNA of interest are injected into one of the pro-nuclei of a fertilized egg. Injection of DNA into the cytoplasm of a zygote can also be employed.

In general, female animals are superovulated by treatment with follicle stimulating hormone, then mated.
35 Fertilized eggs are collected, and the heterologous DNA is injected into the eggs using known methods. See, for example, U.S. Patent No. 4,873,191; Gordon et al., Proc.

Natl. Acad. Sci. USA 77: 7380-7384, 1980; Gordon and Ruddle, Science 214: 1244-1246, 1981; Palmiter and Brinster, Cell 41: 343-345, 1985; Brinster et al., Proc. Natl. Acad. Sci. USA 82: 4438-4442, 1985; Hogan et al.,
5 Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, 1986; Simons et al. Bio/Technology 6: 179-183, 1988; Wall et al., Biol. Reprod. 32: 645-651, 1985; Buhler et al., Bio/Technology 8: 140-143, 1990; Ebert et al., Bio/Technology 9: 835-838,
10 1991; Krimpenfort et al., Bio/Technology 9: 844-847, 1991; Wall et al., J. Cell. Biochem. 49: 113-120, 1992; WIPO publications WO 88/00239, WO 90/05118, and WO 92/11757; and GB 87/00458, which are incorporated herein by reference.

15 For injection into fertilized eggs, the expression units are removed from their respective vectors by digestion with appropriate restriction enzymes. For convenience, it is preferred to design the vectors so that the expression units are removed by cleavage with enzymes
20 that do not cut either within the expression units or elsewhere in the vectors. The expression units are recovered by conventional methods, such as electro-elution followed by phenol extraction and ethanol precipitation, sucrose density gradient centrifugation, or combinations
25 of these approaches.

DNA is injected into eggs essentially as described in Hogan et al., *ibid.* In a typical injection, eggs in a dish of an embryo culture medium are located using a stereo zoom microscope (x50 or x63 magnification
30 preferred). Suitable media include Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid) or bicarbonate buffered media such as M2 or M16 (available from Sigma Chemical Co., St. Louis, USA) or synthetic oviduct medium (disclosed below). The eggs are secured
35 and transferred to the center of a glass slide on an injection rig using, for example, a drummond pipette complete with capillary tube. Viewing at lower (e.g. x4)

magnification is used at this stage. Using the holding pipette of the injection rig, the eggs are positioned centrally on the slide. Individual eggs are sequentially secured to the holding pipette for injection. For each
5 injection process, the holding pipette/egg is positioned in the center of the viewing field. The injection needle is then positioned directly below the egg. Preferably using x40 Nomarski objectives, both manipulator heights are adjusted to focus both the egg and the needle. The
10 pronuclei are located by rotating the egg and adjusting the holding pipette assembly as necessary. Once the pronucleus has been located, the height of the manipulator is altered to focus the pronuclear membrane. The injection needle is positioned below the egg such that the
15 needle tip is in a position below the center of the pronucleus. The position of the needle is then altered using the injection manipulator assembly to bring the needle and the pronucleus into the same focal plane. The needle is moved, via the joy stick on the injection
20 manipulator assembly, to a position to the right of the egg. With a short, continuous jabbing movement, the pronuclear membrane is pierced to leave the needle tip inside the pronucleus. Pressure is applied to the injection needle via, for example, a glass syringe until
25 the pronucleus swells to approximately twice its volume. At this point, the needle is slowly removed. Reverting to lower (e.g. x4) magnification, the injected egg is moved to a different area of the slide, and the process is repeated with another egg.

30 After the DNA is injected, the eggs may be cultured to allow the pronuclei to fuse, producing one-cell or later stage embryos. In general, the eggs are cultured at approximately the body temperature of the species used in a buffered medium containing balanced
35 salts and serum. Surviving embryos are then transferred to pseudopregnant recipient females, typically by inserting them into the oviduct or uterus, and allowed to

develop to term. During embryogenesis, some of the injected DNA integrates in a random fashion in the genomes of a small number of the developing embryos.

Potential transgenic offspring are screened via
5 blood samples and/or tissue biopsies. DNA is prepared from these samples and examined for the presence of the injected construct by techniques such as polymerase chain reaction (PCR; see Mullis, U.S. Patent No. 4,683,202) and Southern blotting (Southern, J. Mol. Biol. 98:503, 1975;
10 Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982). Founder transgenic animals, or G0s, may be wholly transgenic, having transgenes in all of their cells, or mosaic, having transgenes in only a subset of cells (see, for example,
15 Wilkie et al., Develop. Biol. 118: 9-18, 1986). In the latter case, groups of germ cells may be wholly or partially transgenic. In the latter case, the number of transgenic progeny from a founder animal will be less than the expected 50% predicted from Mendelian principles.
20 Founder G0 animals are grown to sexual maturity and mated to obtain offspring, or G1s. The G1s are also examined for the presence of the transgene to demonstrate transmission from founder G0 animals. In the case of male G0s, these may be mated with several non-transgenic
25 females to generate many offspring. This increases the chances of observing transgene transmission. Female G0 founders may be mated naturally, artificially inseminated or superovulated to obtain many eggs which are transferred to surrogate mothers. The latter course gives the best
30 chance of observing transmission in animals having a limited number of young. The above-described breeding procedures are used to obtain animals that can pass the DNA on to subsequent generations of offspring in the normal, Mendelian fashion, allowing the development of,
35 for example, colonies (mice), flocks (sheep), or herds (pigs, goats and cattle) of transgenic animals.

The milk from lactating G0 and G1 females is examined for the expression of the heterologous protein using immunological techniques such as ELISA (see Harlow and Lane, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory, 1988) and Western blotting (Towbin et al., Proc. Natl. Acad. Sci. USA 76: 4350-4354, 1979). For a variety of reasons known in the art, expression levels of the heterologous protein will be expected to differ between individuals.

10 A satisfactory family of animals should satisfy three criteria: they should be derived from the same founder G0 animal; they should exhibit stable transmission of the transgene; and they should exhibit acceptably stable expression levels from generation to generation and
15 from lactation to lactation of individual animals. These principles have been demonstrated and discussed (Carver et al., Bio/Technology 11: 1263-1270, 1993). Animals from such a suitable family are referred to as a "line." Initially, male animals, G0 or G1, are used to derive a
20 flock or herd of producer animals by natural or artificial insemination. In this way, many female animals containing the same transgene integration event can be quickly generated from which a supply of milk can be obtained.

The protein C is recovered from milk using
25 standard practices such as skimming, precipitation, filtration and protein chromatography techniques.

Protein C produced according to the present invention can be activated by removal of the activation peptide from the amino terminus of the heavy chain.
30 Activation can be achieved using methods that are well known in the art, for example, using α -thrombin (Marlar et al., Blood 59:1067-1072, 1982), trypsin (Marlar et al., 1982, *ibid.*), Russel's viper venom factor X activator (Kisiel, J. Clin. Invest. 64:761-769, 1979) or
35 commercially available Protac C (American Diagnostica, NY, NY).

The protein C molecules provided by the present invention and pharmaceutical compositions thereof are particularly useful for administration to humans to treat a variety of conditions involving intravascular coagulation. For instance, although deep vein thrombosis and pulmonary embolism can be treated with conventional anticoagulants, the activated protein C described herein may be used to prevent the occurrence of thromboembolic complications in identified high risk patients, such as those undergoing surgery or those with congestive heart failure. Since activated protein C is more selective than heparin, being active in the body generally when and where thrombin is generated and fibrin thrombi are formed, activated protein C will be more effective and less likely to cause bleeding complications than heparin when used prophylactically for the prevention of deep vein thrombosis. The dose of activated protein C for prevention of deep vein thrombosis is in the range of about 100 µg to 100 mg/day, and administration should begin at least about 6 hours prior to surgery and continue at least until the patient becomes ambulatory. In established deep vein thrombosis and/or pulmonary embolism, the dose of activated protein C ranges from about 100 µg to 100 mg as a loading dose followed by maintenance doses ranging from 3 to 300 mg/day. Because of the lower likelihood of bleeding complications from activated protein C infusions, activated protein C can replace or lower the dose of heparin during or after surgery in conjunction with thrombectomies or embolectomies.

The activated protein C compositions of the present invention will also have substantial utility in the prevention of cardiogenic emboli and in the treatment of thrombotic strokes. Because of its low potential for causing bleeding complications and its selectivity, activated protein C can be given to stroke victims and may prevent the extension of the occluding arterial thrombus.

The amount of activated protein C administered will vary with each patient depending on the nature and severity of the stroke, but doses will generally be in the range of those suggested below.

Pharmaceutical compositions of activated protein C provided herein will be a useful treatment in acute myocardial infarction because of the ability of activated protein C to enhance *in vitro* fibrinolysis. Activated protein C can be given with tissue plasminogen activator or streptokinase during the acute phases of the myocardial infarction. After the occluding coronary thrombus is dissolved, activated protein C can be given for subsequent days or weeks to prevent coronary reocclusion. In acute myocardial infarction, the patient is given a loading dose of at least about 1-500 mg of activated protein C, followed by maintenance doses of 1-100 mg/day.

Activated protein C is useful in the treatment of disseminated intravascular coagulation (DIC). Patients with DIC characteristically have widespread microcirculatory thrombi and often severe bleeding problems which result from consumption of essential clotting factors. Because of its selectivity, activated protein C will not aggravate the bleeding problems associated with DIC, as do conventional anticoagulants, but will retard or inhibit the formation of additional microvascular fibrin deposits.

The invention is further illustrated by the following non-limiting examples.

30 EXAMPLES

Example I

A. Vector pMAD6 Construction

The multiple cloning site of the vector pUC18
35 (Yanisch-Perron et al., Gene 33:103-119, 1985) was removed
and replaced with a synthetic double stranded
oligonucleotide (the strands of which are shown in SEQ ID

NO: 6 and SEQ ID NO: 7) containing the restriction sites Pvu I/Mlu I/Eco RV/Xba I/Pvu I/Mlu I, and flanked by 5' overhangs compatible with the restriction sites Eco RI and Hind III. pUC18 was cleaved with both Eco RI and Hind III, the 5' terminal phosphate groups were removed with calf intestinal phosphatase, and the oligonucleotide was ligated into the vector backbone. The DNA sequence across the junction was confirmed by sequencing, and the new plasmid was called pUCPM.

10 The b-lactoglobulin (BLG) gene sequences from pSSltgXS (disclosed in WIPO publication WO 88/00239) were excised as a Sal I-Xba I fragment and recloned into the vector pUCPM that had been cut with Sal I and Xba I to construct vector pUCXS. pUCXS is thus a pUC18 derivative
15 containing the entire BLG gene from the Sal I site to the Xba I site of phage SS1 (Ali and Clark, J. Mol. Biol. 199: 415-426, 1988).

 The plasmid pSSltgSE (disclosed in WIPO publication WO 88/00239) contains a 1290 bp BLG fragment
20 flanked by Sph I and EcoR I restriction sites, a region spanning a unique Not I site and a single Pvu II site which lies in the 5' untranslated leader of the BLG mRNA. Into this Pvu II site was ligated a double stranded, 8 bp DNA linker (5'-GGATATCC-3') encoding the recognition site
25 for the enzyme Eco RV. This plasmid was called pSSltgSE/RV. DNA sequences bounded by Sph I and Not I restriction sites in pSSltgSE/RV were excised by enzymatic digestion and used to replace the equivalent fragment in pUCXS. The resulting plasmid was called pUCXSRV. The
30 sequence of the BLG insert in pUCXSRV is shown in SEQ ID NO: 5, with the unique Eco RV site at nucleotide 4245 in the 5' untranslated leader region of the BLG gene. This site allows insertion of any additional DNA sequences under the control of the BLG promoter 3' to the
35 transcription initiation site.

 Using the primers BLGAMP3 (5'-TGG ATC CCC TGC CGG TGC CTC TGG-3'; SEQ ID NO: 8) and BLGAMP4 (5'-AAC GCG

TCA TCC TCT GTG AGC CAG-3'; SEQ ID NO: 9) a PCR fragment of approximately 650 bp was produced from sequences immediately 3' to the stop codon of the ELG gene in pUCXSRV. The PCR fragment was engineered to have a BamH I site at its 5' end and an Mlu I site at its 3' end and was
5 cloned as such into BamH I and Mlu I cut pGEM7zf(+) (Promega) to give pDAM200(+).

pUCXSRV was digested with Kpn I, and the largest, vector containing band was gel purified. This
10 band contained the entire pUC plasmid sequences and some 3' non-coding sequences from the BLG gene. Into this backbone was ligated the small Kpn I fragment from pDAM200(+) which, in the correct orientation, effectively engineered a Bam HI site at the extreme 5' end of the 2.6
15 Kbp of the BLG 3' flanking region. This plasmid was called pBLAC200. A 2.6 Kbp Cla I-Xba I fragment from pBLAC200 was ligated into Cla I-Xba I cut pSP72 vector (Promega), thus placing an Eco RV site immediately upstream of the BLG sequences. This plasmid was called
20 pBLAC210.

The 2.6 Kbp Eco RV-Xba I fragment from pBLAC210 was ligated into Eco RV-Xba I cut pUCXSRV to form pMAD6 (SEQ ID NO: 23). This, in effect, excised all coding and intron sequences from pUCXSRV, forming a BLG minigene
25 consisting of 4.2 Kbp of 5' promoter and 2.6 Kbp of 3' downstream sequences flanking a unique Eco RV site. An oligonucleotide linker (ZC6839: ACTACGTAGT; SEQ ID NO: 10) was inserted into the Eco RV site of pMAD6 (SEQ ID NO: 23). This modification destroyed the Eco RV site and
30 created a Sna BI site to be used for cloning purposes. The vector was designated pMAD6-Sna. Messenger RNA initiates upstream of the Sna BI site and terminates downstream of the Sna BI site. The precursor transcript will encode a single BLG-derived intron, intron 6, which
35 is entirely within the 3' untranslated region of the gene.

B. Intronless Vector pMAD

The beta-lactoglobulin cloning vector pMAD was also constructed to allow the insertion of cDNAs under the control of the beta-lactoglobulin gene promoter in constructs containing no introns. To generate pMAD, the plasmid pBLAC100 was opened by digestion with both Eco RV and Sal I. The vector fragment was gel purified and the linearized vector was ligated with the 4.2 kb promoter fragment from the plasmid pUCXSRV as a Sal I-Eco RV fragment. The resulting construct was designated pST1 and constitutes a beta-lactoglobulin mini-gene encompassing a 4.2 kb of promoter region and 2.1 kb of 3' non-coding region beginning immediately downstream of the beta-lactoglobulin translational termination codon. A unique Eco RV site allows blunt-end cloning of any additional DNA sequences. To generate transgenic animals it is generally accepted in the art and preferred to separate bacterial plasmid vector sequences from those intended to be used in the generation of transgenic animals. In order to allow the practical excision of novel cDNA based constructs using this beta-lactoglobulin mini-gene, the minigene was excised from pST1 on a Xho I-Not I fragment, the DNA termini made flush with Klenow polymerase and the product was ligated into the Eco RV site of pUCPM to yield pMAD. Digestion with Mlu I liberates beta-lactoglobulin-cDNA constructs from the bacterial vector backbone.

Intronless constructs based on cDNAs and vectors such as pMAD benefit from the use of "rescue technology" for efficient expression. Rescue technology takes advantage of the ability of a co-injected and co-integrated BLG gene to improve the expression levels obtained from intronless, cDNA-based constructs in the transgenic system. Rescue technology is disclosed in WIPO publication WO 92/11358, and is incorporated herein by reference.

Example 2A. Isolation of cDNA

A cDNA sequence coding for human protein C was prepared as described in U.S. Patent 4,959,318, which is incorporated herein by reference. Briefly, a genomic fragment containing an exon corresponding to amino acids -42 to -19 (SEQ ID NO: 1) of the pre-pro peptide of protein C was isolated, nick translated and used as a probe to screen a cDNA library constructed by the technique of Gubler and Hoffman, Gene 25:263-269, 1983, using mRNA from HepG2 cells. This cell line was derived from human hepatocytes and was previously shown to synthesize protein C (Fair and Bahnak, Blood 64:194-204, 1984). Positive clones comprising cDNA inserted into the Eco RI site of phage λ gt11 were isolated and screened with an oligonucleotide probe corresponding to the 5' non-coding region of the protein C gene. One clone was also positive with this probe and its entire nucleotide sequence was determined. The cDNA contained 70 bp of 5' untranslated sequence, the entire coding sequence for human prepro-protein C, and the entire 3' non-coding region corresponding to the second polyadenylation site.

B. Subcloning of Protein C cDNA

The vector pDX was derived from pD3, which was generated from plasmid pDHFRIII (Berkner et al., Nuc. Acids Res. 13:841-857, 1985). The Pst I site immediately upstream from the DHFR sequence in pDHFRIII was converted to a Bcl I site by digestion with Pst I. The DNA was phenol extracted, ethanol precipitated and resuspended in buffer B (50 mM Tris pH 8, 7 mM MgCl₂, 7 mM β -MSH). A ligation reaction containing the linearized plasmid DNA and Bcl I linkers was done. The resulting plasmid was phenol extracted, ethanol precipitated and digested with Bcl I and gel purified. The gel purified plasmid DNA was circularized by ligation and used to transform E. coli HB101. Positive colonies were identified by restriction

analysis and designated pDHFR'. DNA from positive colonies was isolated and used to transform dam⁻ E. coli.

Plasmid pD2' was generated by cleaving pDHFR' and pSV40 (comprising Bam HI digested SV40 DNA cloned into the Bam HI site of pML-1 (Lusky et al., Nature 293:79-81, 1981)) with Bcl I and Bam HI. The DNA fragments were resolved by gel electrophoresis, and the 4.9 kb pDHFR' fragment and 0.2 kb SV40 fragment were isolated. These fragments were used in a ligation reaction, and the resulting plasmid, designated pD2', was used to transform E. coli RRI.

Plasmid pD2' was modified by deleting the "poison" sequences in the pBR322 region (Lusky et al., 1981, *ibid.*). Plasmids pD2' and pML-1 were digested with Eco RI and Nru I. The 1.7 kb pD2' fragment and 1.8 kb pML-1 fragment were isolated by gel purification, circularized in a ligation reaction and used to transform E. coli HB101. Positive colonies were identified using restriction analysis (designated pD2) and digested with Eco RI and Bcl I. A 2.8 kb fragment (fragment C) was isolated and gel purified.

To generate the remaining fragments used in constructing pD3, pDHFRIII was modified to convert the Sac II (Sst II) site into either a Hind III or Kpn I site. pDHFRIII was digested with Sst II and ligation reactions with either Hind III or Kpn I linkers were done. The resultant plasmids were digested with either Hind III or Kpn I and gel purified. The resultant plasmids were designated either pDHFRIII (Hind III) or pDHFRIII (Kpn I). A 700 bp KpnI-Bgl II fragment (fragment A) was purified from pDHFRIII (Hind III).

The SV40 enhancer sequence was inserted into pDHFRIII (Hind III) by first digesting SV40 DNA with Hind III, and DNA from 5089 to 968 bp was isolated and purified. Plasmid pDHFRIII (Hind III) was phosphatased, and the SV40 DNA and linearized plasmid pDHFRIII (Hind III) were used in a ligation reaction. A 700 bp Eco RI-

Kpn I fragment (fragment B) was isolated from the resulting plasmid.

For the final construction of pD3, fragments A (50 ng), B (50 ng) and C (10 ng) were combined in a ligation reaction and used to transform E. coli RRI. Positive colonies were isolated and plasmid DNA was prepared.

Plasmid pD3 was modified to accept the insertion of the protein C sequence by converting the Bcl I insertion site to an Eco RI site. First, the Eco RI site present in pD3 (the leftmost terminus in adenovirus 5 0-1) was converted to a Bam HI site via conventional linker procedures. The resultant plasmid was transformed in E. coli HB101. Plasmid DNA was prepared, and positive clones were identified by restriction analysis.

pD3' is a vector identical to pD3 except that the SV40 polyadenylation signal (i.e., the SV40 Bam HI (2533 bp) to Bcl I (2770 bp) fragment) is in the late orientation. Thus, pD3' contains a Bam HI site as the site of gene insertion.

To generate pDX, the Eco RI site in pD3' was converted to a Bcl I site by Eco RI cleavage, incubation with SI nuclease and subsequent ligation with Bcl I linkers. DNA was prepared from a positively identified colony, and a 1.9 kb Xho I-Pst I fragment containing the altered restriction site was prepared via gel purification. In a second modification, Bcl I-cleaved pD3 was ligated with Eco RI-Bcl I adapters in order to generate an Eco RI site as the position for inserting a gene into the expression vector. Positive colonies were identified by restriction analysis. The resulting plasmid, designated pDX, has a unique Eco RI site for insertion of foreign genes.

The protein C cDNA was inserted into pDX as an Eco RI fragment. Plasmids were screened by restriction analysis. A plasmid having the protein C insert in the correct orientation with respect to the promoter elements

and plasmid DNA was designated pDX/PC. Because the cDNA insert in pDX/PC contains a ATG codon in the 5' non-coding region, deletion mutagenesis was performed on the cDNA. Deletion of the three base pairs was performed according to standard procedures or oligonucleotide-directed mutagenesis. The pDX-based vector containing the modified cDNA was designated p594.

C. Modification of the Protein C Processing Site

To enhance the processing of single-chain protein C to the two-chain form, two additional arginine residues were introduced immediately upstream of the Lys₁₅₆-Arg₁₅₇ cleavage site of the precursor protein, resulting in a cleavage site consisting of four basic amino acids, Arg-Arg-Lys-Arg (SEQ ID NO: 20). The resultant mutant precursor of protein C was designated PC962. It contains the sequence Ser-His-Leu-Arg-Arg-Lys-Arg-Asp (SEQ ID NO: 22) at the cleavage site. Processing at the Arg-Asp bond results in a two-chain protein C molecule.

The mutant molecule was generated by altering the cloned cDNA by site-specific mutagenesis (essentially as described by Zoller and Smith, *DNA* 3:479-488, 1984, for the two-primer method) using the mutagenic oligonucleotide ZC962 (5'AGTCACCTGAGAAGAAAACGAGACA³'; SEQ ID NO: 11). Plasmid p594 was digested with Sst I, and the approximately 87 bp fragment was cloned into M13mp11 and single-stranded template DNA was isolated. Following mutagenesis, a correct clone was identified by sequencing. Replicative form DNA was isolated, digested with Sst I, and the protein C fragment was inserted into Sst I-cut p594. Clones having the Sst I fragment inserted in the desired orientation were identified by restriction enzyme mapping. The resulting expression vector was designated pDX/PC962.

D. Intronless Protein C Construct

To facilitate the cloning of the protein C cDNA, PC962, into pMAD, the cDNA contained in pEX/PC962 was modified to incorporate Eco RV sites at the extremities of the protein C cDNA insert. A 769 bp Sst II-Pst I fragment encompassing the 3' end of PC962 was cloned between the Sst II and Pst I sites of pBluescript II SK⁺ (Stratagene, La Jolla, CA). The fragment was excised with Sst II and Eco RV and purified. The 5' portion of PC962 was modified by PCR. The sense oligonucleotide primer for this reaction covered the 5' ATG region of the cDNA and provided an Eco RV site upstream of this in the product. The antisense oligonucleotide primer covered the Sst II site used to generate the Sst II-Eco RV fragment. The resulting PCR product was digested with Eco RV and Sst II and ligated with the Sst II-Eco RV 3' fragment and Eco RV digested pMAD. The resulting plasmid, designated pCORP9 effectively contained the PC962 cDNA flanked by Eco RV sites in an intronless fusion driven by the beta-lactoglobulin promoter.

E. Genomic Protein C DNA Construction

A genomic DNA construct containing exons I through VIII was made. See, U.S. Patent 4,959,318, which is incorporated herein by reference, for disclosure of the exon structure of the protein C gene. This genomic construct, designated GPC10-1, changed the sequence 16 base pairs upstream of the ATG from the native protein C sequence to the beta-lactoglobulin sequence and introduced mutations in the propeptide cleavage site located in exon 2, and the two-chain cleavage site located in exon 6, as described below.

The construct was assembled using four fragments designated A, B, C and D and encompassed the protein C gene sequence from the ATG to a Bam HI site in exon VIII, immediately upstream of the stop codon. The fragments were generated from a human genomic library in λ Charon 4A phage that was screened with a radiolabeled cDNA probe for

human protein C. The screening of the λ library produced three clones that together mapped the entire protein C gene (Foster et al., 1985, *ibid.*). These clones were designated PC λ 1, PC λ 6 and PC λ 8.

5 Fragment A was a Not I to Eco RI fragment that contained exons I and II of the genomic sequence and was 1698 bp. A subclone of PC λ 6 contained an Eco RI to Eco RI fragment and was designated pHCR4.4-1. Using pHCR4.4-1 as a template and oligonucleotides ZC6303 (SEQ ID NO: 12) and
10 ZC6337 (SEQ ID NO: 13), a DNA fragment was generated by polymerase chain reaction (PCR). Oligonucleotide ZC6303 changed the sequence 16 base pairs 5' to the ATG sequence from the native protein C sequence to the equivalent sequence from the beta-lactoglobulin gene and introduced a
15 Not I site. Oligonucleotide ZC6337 changed the propeptide cleavage site from Arg-Ile-Arg-Lys-Arg (SEQ ID NO: 24) to Gln-Arg-Arg-Lys-Arg (SEQ ID NO: 25). The resulting PCR-generated fragment was digested with Not I and Bss HII, and a 1402 base pair fragment was gel purified and
20 designated A1. A second fragment was prepared using a λ gt11 clone of PC λ 1 as a template with oligonucleotides ZC6306 (SEQ ID NO: 14) and ZC6338 (SEQ ID NO: 15) in a polymerase chain reaction. The resulting DNA fragment, designated A3, was digested with Bss HII and Eco RI and
25 gel purified, resulting in a 296 base pair fragment. Fragments A1 and A3 were ligated into the Bluescript II KS[®] phagemid vector (Stratagene, La Jolla, CA). The resulting plasmid, designated GPC 2-2, was digested with Not I and Eco RI, gel purified and the Not I-Eco RI DNA
30 fragment was designated Fragment A.

 pCR 2-14 is a subclone that contains an Eco RI to Eco RI DNA fragment of PC λ 8 (Foster et al., 1985, *ibid.*). The plasmid was digested with Eco RI and Sst I and gel purified. The resulting fragment was designated
35 Fragment B.

 Plasmid pCR 2-14 was used as template DNA with oligonucleotides ZC6373 (SEQ ID NO: 16) and ZC6305 (SEQ ID

NO: 17), which introduced an Afl II site and the RRKR mutation of the native (KR) two-chain cleavage site, in a polymerase chain reaction. The resulting PCR-generated fragment was digested with Bgl II and Afl II and gel purified, resulting in a 1441 base pair fragment, designated E1. Fragment E1 was used in a ligation reaction with oligonucleotides ZC6302 (SEQ ID NO: 18) and ZC6304 (SEQ ID NO: 19). These oligonucleotides form Afl II and Sst II restriction sites when annealed and were ligated to the 3' end of fragment E1, resulting in a fragment with a 5' Bgl II site and a 3' Sst II site. This fragment was used in a ligation reaction with a Bam HI-Sst II digested Bluescript II KS[®] phagemid vector (Stratagene). The resulting plasmid was designated GPC 8-5 and digested with Sst I and Sst II, generating a 626 base pair fragment, designated Fragment C.

A fourth fragment was generated by digestion of a genomic subclone (pHCB7-1) of PC λ 8. pHCB7-1 contained a Bgl II to Bgl II fragment that encompassed exons VI through VIII. pHCB7-1 was digested with Sst II and Bam HI and a 2702 base pair fragment was gel purified. The fragment was designated Fragment D.

A five-part ligation reaction was prepared using Not I and Bam HI digested and linearized Bluescript II KS[®] phagemid vector (Stratagene) with Fragment A (5' Not I to 3' Eco RI) that contained exons I and II, Fragment B (5' Eco RI to 3' Sst I) that contained exons III, IV and V, Fragment C (5' Sst I to 3' Sst II) that contained the 5' portion of exon VI and Fragment D (5' Sst II to 3' Bam HI) that contained the remaining 3' portion of exon VI and exons VII and VIII. The resulting DNA was 8950 base pairs and designated GPC 10-1.

GPC10-1 was originally generated with BLG sequences and a Not I site upstream of the ATG initiator codon and modifications to both cleavage sites. A clone, designated pPC12/BS, was generated to ensure that the 5' Not I site of GPC10-1 would not introduce secondary

structure into mRNA molecules that could hinder translation. pPC12/BS was generated using PCR amplification of a 1 kb Not I-Sca I fragment that covered the 5' region of the protein C gene and contained the wild-type ATG codon environment. This introduced an Eco RV site immediately downstream of the Not I site, adjacent to the ATG codon, and a Bam HI site was incorporated 3' of the Sca I site to facilitate cloning. Following a Not I/Bam HI digestion, the PCR product was cloned into Not I-Bam HI digested Bluescript II KS[®] phagemid vector (Stratagene). The Not I-Eco RV-Sca I fragment present in pPC12/BS was excised, purified and ligated to GPC10-1, which had been linearized with Not I and partially digested with Sca I (the pUC ampicillin gene has an internal Sca I site). The resulting clone was designated GPC10-2 and possesses an Eco RV site immediately upstream of the ATG initiator codon.

GPC10-1 and GPC10-2 both terminated at the final Bam HI site in exon VIII of the protein C gene. To reconstitute the 56 bp of sequence, ending at the termination codon, two oligonucleotides were synthesized with flanking Bam HI (5') and Bgl II (3') restriction sites. Following annealing of the oligonucleotides, the product was cloned into Bam HI digested pBST+ to generate plasmid pPC3'. pBST+ is a derivative of pBS (Stratagene) with a new polylinker. The addition of the polylinker added Bgl II, Xho I, Nar I and Cla I restriction sites from the vector polylinker downstream of the destroyed Bgl II site of the oligonucleotide construct.

The Not I-Bam HI fragment of GPC10-1 was subcloned into Not I/Bam HI digested pPC3' to add 3' coding sequences of protein C, the TAG termination codon followed by Bgl II-Xho I-Nar I-Cla I. The 3' region of the protein C gene beginning with the Eco RV site in intron V was excised from this plasmid on an Eco RV-Cla I fragment.

The Eco RV-Eco RV fragment from GPC10-2, covering the 5' portion of the protein C gene, and the above Eco RI-Cla I fragment covering the 3' portion of the protein C gene were combined between the Eco RV and Cla I sites of pMAD6 (SEQ ID NO: 23) to generate pCORP13. This effectively placed a genomic portion of the protein C gene with modified propeptide and two-chain cleavage sites under the control of the beta-lactoglobulin promoter.

A further genomic construct was generated from pCORP13 that contained only the modified two-chain cleavage site. This was achieved using PCR amplification to modify two fragments which resulting in restoration of the coding capability of exon 2 from the mutant Gln-Arg-Arg-Lys-Arg (SEQ ID NO: 25) to the wild-type Arg-Ile-Arg-Lys-Arg (SEQ ID NO: 24). pCORP13 was used as template for these reactions. The first fragment was 1.3 kb, which encompassed the 5' end of the protein C gene up to the Bam HI site in exon 2. For this reason, the sense primer was designed to add a Hind III site 5' to the Eco RV site proximal to the ATG initiation codon. The antisense primer was designed to restore the wild-type sequences in exon 2, which included a restored Bam HI site. A second fragment of 0.2 kb from the Bam HI site in exon 2 to the Xho I site in intron 2, was also amplified. The two fragments were combined in pGEMII (Promega, Madison, WI) to generate pGEMPC1.5. A 7.5 kb Xho I fragment from pCORP13 was ligated to Xho I digested pGEMPC1.5 to generate a complete protein C genomic sequence covering exons 1-8 with a wild-type propeptide cleavage site and a modified two-chain cleavage site. The plasmid was designated pGEMPC14. The sequence was excised from pGEMPC14 as a Hind III/Sal I fragment. The DNA termini were repaired using a Klenow reaction and the fragment was blunt-end ligated into Eco RV digested pMAD6 (SEQ ID NO: 23) to generate pCORP14.

Example 3

Mice for initial breeding stocks (C57BL6J, CBACA) were obtained from Harlan Olac Ltd. (Bicester, UK). These were mated in pairs to produce F1 hybrid cross (B6CBAF1) for recipient females, superovulated females, stud males and vasectomized males. All animals were kept on a 14 hour light/10 hour dark cycle and fed water and food (Special Diet Services RM3, Edinburgh, Scotland) *ad libitum*.

Transgenic mice were generated essentially as described in Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, 1986, which is incorporated herein by reference in its entirety. Female B6CBAF1 animals were superovulated at 4-5 weeks of age by an i.p. injection of pregnant mares' serum gonadotrophin (FOLLIGON, Vet-Drug, Falkirk, Scotland) (5 iu) followed by an i.p. injection of human chorionic gonadotrophin (CHORULON, Vet-Drug, Falkirk, Scotland) (5 iu) 45 hours later. They were then mated with a stud male overnight. Such females were next examined for copulation plugs. Those that had mated were sacrificed, and their eggs were collected for microinjection.

DNA was injected into the fertilized eggs as described in Hogan et al. (*ibid.*). Briefly, the vector containing the protein C expression unit was digested with Mlu I, and the expression unit was isolated by sucrose gradient centrifugation. All chemicals used were reagent grade (Sigma Chemical Co., St. Louis, MO, U.S.A.), and all solutions were sterile and nuclease-free. Solutions of 20% and 40% sucrose in 1 M NaCl, 20 mM Tris pH 8.0, 5 mM EDTA were prepared using UHP water and filter sterilized. A 30% sucrose solution was prepared by mixing equal volumes of the 20% and 40% solutions. A gradient was prepared by layering 0.5 ml steps of the 40%, 30% and 20% sucrose solutions into a 2 ml polyallomer tube and allowed to stand for one hour. 100 μ l of DNA solution (max. 8 μ g DNA) was loaded onto the top of the gradient, and the

gradient was centrifuged for 17-20 hours at 26,000 rpm, 15°C in a Beckman TL100 ultracentrifuge using a TLS-55 rotor (Beckman Instruments, Fullerton, CA, USA). Gradients were fractionated by puncturing the tube bottom with a 20 ga. needle and collecting drops in a 96 well microtiter plate. 3 µl aliquots were analyzed on a 1% agarose mini-gel. Fractions containing the protein C DNA fragment were pooled and ethanol precipitated overnight at -20°C in 0.3M sodium acetate. DNA pellets were resuspended in 50-100 µl UHP water and quantitated by fluorimetry. The protein C expression unit was diluted in Dulbecco's phosphate buffered saline without calcium and magnesium (containing, per liter, 0.2 g KCl, 0.2 g KH₂PO₄, 8.0 g NaCl, 1.15 g Na₂HPO₄) or in TE (10 mM Tris-HCl, 1 mM EDTA pH 7.5). DNA concentration is adjusted to about 6 µg/ml, prior to injection into the eggs (~2 pl total DNA solution per egg).

Recipient females of 6-8 weeks of age are prepared by mating B6CBAF1 females in natural estrus with vasectomized males. Females possessing copulation plugs are then kept for transfer of microinjected eggs.

Following birth of potential transgenic animals, tail biopsies are taken, under anesthesia, at four weeks of age. Tissue samples are placed in 2 ml of tail buffer (0.3 M Na acetate, 50 mM NaCl, 1.5 mM MgCl₂, 10 mM Tris-HCl, pH 8.5, 0.5% NP40, 0.5% Tween 20) containing 200 µg/ml proteinase K (Boehringer Mannheim, Mannheim, Germany) and vortexed. The samples are shaken (250 rpm) at 55°-60°C for 3 hours to overnight. DNA prepared from biopsy samples is examined for the presence of the injected constructs by PCR and Southern blotting. The digested tissue is vigorously vortexed, and 5 µl aliquots are placed in 0.5 ml microcentrifuge tubes. Positive and negative tail samples are included as controls. Forty µl of silicone oil (BDH, Poole, UK) is added to each tube, and the tubes are briefly centrifuged. The tubes are incubated in the heating block of a thermal cycler (e.g.

Omni-gene, Hybaid, Teddington, UK) to 95°C for 10 minutes. Following this, each tube has a 45 μ l aliquot of PCR mix added such that the final composition of each reaction mix is: 50 mM KCl; 2 mM MgCl₂; 10 mM Tris-HCl (pH 8.3); 0.01% gelatin; 0.1% NP40, 10% DMSO; 500 nM each primer, 200 μ M dNTPs; 0.02 U/ μ l Taq polymerase (Boehringer Mannheim, Mannheim, Germany). The tubes are then cycled through 30 repeated temperature changes as required by the particular primers used. The primers may be varied but in all cases must target the BLG promoter region. This is specific for the injected DNA fragments because the mouse does not have a BLG gene. Twelve μ l of 5x loading buffer containing Orange G marker dye (0.25% Orange G (Sigma) 15% Ficoll type 400 (Pharmacia Biosystems Ltd., Milton Keynes, UK)) is then added to each tube, and the reaction mixtures are electrophoresed on a 1.6% agarose gel containing ethidium bromide (Sigma) until the marker dye has migrated 2/3 of the length of the gel. The gel is visualized with a UV light source emitting a wavelength of 254 nm. Transgenic mice having one or more of the injected DNA fragments are identified by this approach.

Positive tail samples are processed to obtain pure DNA. The DNA samples are screened by Southern blotting using a BLG promoter probe (nucleotides 2523-4253 of SEQ ID NO: 7).

Southern blot analysis of transgenic mice prepared essentially as described above demonstrated that approximately 10% of progeny contained protein C sequences. Examination of milk from positive animals by reducing SDS polyacrylamide gel electrophoresis demonstrated the presence of protein C at concentrations up to 1 mg/ml.

Example 4

Donor ewes are treated with an intravaginal progesterone-impregnated sponge (CHRONOGEST Goat Sponge,

Intervet, Cambridge, UK) on day 0. Sponges are left *in situ* for ten or twelve days.

Superovulation is induced by treatment of donor ewes with a total of one unit of ovine follicle stimulating hormone (OFSH) (OVAGEN, Horizon Animal
5 Reproduction Technology Pty. Ltd., New Zealand) administered in eight intramuscular injections of 0.125 units per injection starting at 5:00 pm on day -4 and ending at 8:00 am on day 0. Donors are injected
10 intramuscularly with 0.5 ml of a luteolytic agent (ESTRUMATE, Vet-Drug) on day -4 to cause regression of the corpus luteum, to allow return to estrus and ovulation. To synchronize ovulation, the donor animals are injected intramuscularly with 2 ml of a synthetic releasing hormone
15 analog (RECEPTAL, Vet-Drug) at 5:00 pm on day 0.

Donors are starved of food and water for at least 12 hours before artificial insemination (A.I.). The animals are artificially inseminated by intrauterine laparoscopy under sedation and local anesthesia on day 1.
20 Either xylazine (ROMPUN, Vet-Drug) at a dose rate of 0.05-0.1 ml per 10 kg bodyweight or ACP injection 10 mg/ml (Vet-Drug) at a dose rate of 0.1 ml per 10 kg bodyweight is injected intramuscularly approximately fifteen minutes before A.I. to provide sedation. A.I. is carried out
25 using freshly collected semen from a Poll Dorset ram. Semen is diluted with equal parts of filtered phosphate buffered saline, and 0.2 ml of the diluted semen is injected per uterine horn. Immediately pre- or post-A.I., donors are given an intramuscular injection of AMOXYPEN
30 (Vet-Drug).

Fertilized eggs are recovered on day 2 following starvation of donors of food and water from 5:00 pm on day 1. Recovery is carried out under general anesthesia induced by an intravenous injection of 5% thiopentone sodium (INTRAVAL SODIUM, Vet-Drug) at a dose rate of 3 ml
35 per 10 kg bodyweight. Anesthesia is maintained by inhalation of 1-2% Halothane/O₂/N₂O. To recover the

fertilized eggs, a laparotomy incision is made, and the uterus is exteriorized. The eggs are recovered by retrograde flushing of the oviducts with Ovum Culture Medium (Advanced Protein Products, Brierly Hill, West Midlands, UK) supplemented with bovine serum albumin of New Zealand origin. After flushing, the uterus is returned to the abdomen, and the incision is closed. Donors are allowed to recover post-operatively or are euthanized. Donors that are allowed to recover are given an intramuscular injection of Amoxypen L.A. at the manufacturer's recommended dose rate immediately pre- or post-operatively.

Plasmids containing the protein C DNA are digested with Mlu I, and the expression unit fragments are recovered and purified on sucrose density gradients. The fragment concentrations are determined by fluorimetry and diluted in Dulbecco's phosphate buffered saline without calcium and magnesium or TE as described above. The concentration is adjusted to 6 lg/ml, and approximately 2 pl of the mixture is microinjected into one pronucleus of each fertilized eggs with visible pronuclei.

All fertilized eggs surviving pronuclear microinjection are cultured in vitro at 38.5°C in an atmosphere of 5% CO₂:5% O₂:90% N₂ and about 100% humidity in a bicarbonate buffered synthetic oviduct medium (see Table) supplemented with 20% v/v vasectomized ram serum. The serum may be heat inactivated at 56°C for 30 minutes and stored frozen at -20°C prior to use. The fertilized eggs are cultured for a suitable period of time to allow early embryo mortality (caused by the manipulation techniques) to occur. These dead or arrested embryos are discarded. Embryos having developed to 5 or 6 cell divisions are transferred to synchronized recipient ewes.

Table
Synthetic Oviduct Medium

5	<u>Stock A (Lasts 3 Months)</u>	
	NaCl	6.29 g
	KCl	0.534 g
	KH ₂ PO ₄	0.162 g
	MgSO ₄ ·7H ₂ O	0.182 g
10	Penicillin	0.06 g
	Sodium Lactate 60% syrup	0.6 mls
	Super H ₂ O	99.4 mls
15	<u>Stock B (Lasts 2 weeks)</u>	
	NaHCO ₃	0.21 g
	Phenol red	0.001 g
	Super H ₂ O	10 mls
20	<u>Stock C (Lasts 2 weeks)</u>	
	Sodium Pyruvate	0.051 g
	Super H ₂ O	10 mls
25	<u>Stock D (Lasts 3 months)</u>	
	CaCl ₂ ·2H ₂ O	0.262 g
	Super H ₂ O	10 mls
30	<u>Stock E (Lasts 3 months)</u>	
	Hepes	0.651 g
	Phenol red	0.001 g
	Super H ₂ O	10 mls
35	<u>To make up 10mls of Bicarbonate Buffered Medium</u>	
	STOCK A	1 ml
	STOCK B	1 ml
	STOCK C	0.07 ml
	STOCK D	0.1 ml
	Super H ₂ O	7.83 ml
40	Osmolarity should be 265-285 mOsm. Add 2.5 ml of heat inactivated sheep serum and filter sterilize.	
45	<u>To make up 10 mls of HEPES Buffered Medium</u>	
	STOCK A	1 ml
	STOCK B	0.2 ml
	STOCK C	0.07 ml
	STOCK D	0.1 ml
	STOCK E	0.8 ml
50	Super H ₂ O	7.83 ml

Table. cont.

- 5 Osmolarity should be 265-285 mOsm.
 Add 2.5 ml of heat inactivated sheep serum
 and filter sterilize.

 Recipient ewes are treated with an intravaginal
 progesterone-impregnated sponge (Chronogest Ewe Sponge or
10 Chronogest Ewe-Lamb Sponge, Intervet) left in situ for 10
 or 12 days. The ewes are injected intramuscularly with
 1.5 ml (300 iu) of a follicle stimulating hormone
 substitute (P.M.S.G., Intervet) and with 0.5 ml of a
 luteolytic agent (Estrumate, Coopers Pitman-Moore) at
15 sponge removal on day -1. The ewes are tested for estrus
 with a vasectomized ram between 8:00 am and 5:00 pm on
 days 0 and 1.

 Embryos surviving in vitro culture are returned
 to recipients (starved from 5:00 pm on day 5 or 6) on day
20 6 or 7. Embryo transfer is carried out under general
 anesthesia as described above. The uterus is exteriorized
 via a laparotomy incision with or without laparoscopy.
 Embryos are returned to one or both uterine horns only in
 ewes with at least one suitable corpora lutea. After
25 replacement of the uterus, the abdomen is closed, and the
 recipients are allowed to recover. The animals are given
 an intramuscular injection of Amoxypen L.A. at the
 manufacturer's recommended dose rate immediately pre- or
 post-operatively.

30 Lambs are identified by ear tags and left with
 their dams for rearing. Ewes and lambs are either housed
 and fed complete diet concentrates and other supplements
 and or ad lib. hay, or are let out to grass.

 Within the first week of life (or as soon
35 thereafter as possible without prejudicing health), each
 lamb is tested for the presence of the heterologous DNA by
 two sampling procedures. Following tail biopsy, within a
 week, a 10 ml blood sample is taken from the jugular vein
 into an EDTA vacutainer. Tissue samples are taken by tail

biopsy as soon as possible after the tail has become desensitized after the application of a rubber elastrator ring to its proximal third (usually within 200 minutes after "tailing"). The tissue is placed immediately in a solution of tail buffer. Tail samples are kept at room temperature and analyzed on the day of collection. All lambs are given an intramuscular injection of Amoxypen L.A. at the manufacturer's recommended dose rate immediately post-biopsy, and the cut end of the tail is sprayed with an antibiotic spray.

DNA is extracted from sheep blood by first separating white blood cells. A 10 ml sample of blood is diluted in 20 ml of Hank's buffered saline (HES; obtained from Sigma Chemical Co.). Ten ml of the diluted blood is layered over 5 ml of Histopaque (Sigma) in each of two 15 ml screw-capped tubes. The tubes are centrifuged at 3000 rpm (2000 x g max.), low brake for 15 minutes at room temperature. White cell interfaces are removed to a clean 15 ml tube and diluted to 15 ml in HBS. The diluted cells are spun at 3000 rpm for 10 minutes at room temperature, and the cell pellet is recovered and resuspended in 2-5 ml of tail buffer.

To extract DNA from the white cells, 10% SDS is added to the resuspended cells to a final concentration of 1%, and the tube is inverted to mix the solution. One mg of fresh proteinase K solution is added, and the mixture is incubated overnight at 45°C. DNA is extracted using an equal volume of phenol/chloroform (x3) and chloroform/isoamyl alcohol (x1). The DNA is then precipitated by adding 0.1 volume of 3 M NaOAc and 2 volumes of ethanol, and the tube is inverted to mix. The precipitated DNA is spooled out using a clean glass rod with a sealed end. The spool is washed in 70% ethanol, and the DNA is allowed to partially dry, then is redissolved in TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5).

DNA samples from blood and tail are analyzed by Southern blotting using probes for the BLG promoter region and the protein C coding regions.

5 Example 5

A founder female animal, designated 30851, which is transgenic for both BLG and pCORP9 was generated. She has given rise to two sons and a transgenic daughter, designated 40387. Recombinant transgenic protein C was
10 purified from milk (from 30851) by a single chromatography step using a calcium-dependent monoclonal antibody affinity column. Briefly, the milk samples were pooled up to a volume of 40 ml. Two volumes of ice-cold 1 X TBS (50 mM Tris-HCl, 150 mM NaCl pH 6.5) and 200 mM EDTA, pH 6.5
15 were added to solubilise the caseins. The EDTA-treated milk solution was centrifuged at 15,000 rpm for 30 minutes at 4°C in a JA20 rotor (Beckman Instruments, Irvine, CA). After centrifugation, the upper lipid phase and the small pellet were discarded.

20 The EDTA-treated milk was diluted with an equal volume of ice-cold 1 X TBS and 133 mM CaCl_2 while stirring. A cloudy precipitate formed upon addition of the CaCl_2 . The pH was quickly adjusted by addition of a few drops of 4 M NaOH, and the precipitate was
25 redissolved. Any remaining insoluble material was removed by filtration through a 0.45 μm filter.

The optical density of the solubilised milk was measured at 280 nm, and the protein concentration was calculated. The milk was diluted to a protein
30 concentration of 10 mg/ml using 1 X TBS containing CaCl_2 to give a final Ca^{++} concentration of 25 mM. The milk was used to resuspend antibody-Sepharose that carried the immobilized Ca^{++} -dependent monoclonal antibody PCL-2, and had been washed in 1 X TBS and 25 mM CaCl_2 . PCL-2 is a
35 monoclonal antibody that binds single chain and two chain protein C, whether or not they are gamma-carboxylated. The milk-Sepharose mixture was incubated overnight at 4°C.

The matrix was washed twice in batch with 1 x TBS and 25 mM CaCl_2 and packed into a glass column. The resin was washed at a flow rate of 1 ml/min with a calcium containing buffer and a stable baseline was achieved before the bound protein was eluted with an isocratic elution using 1 X TBS and 25 mM EDTA, pH 6.5. Fractions containing protein C were pooled and concentrated to approximately 1 ml using an Amicon ultrafiltration unit with a 10 kDa cut-off membrane (Amicon, Danvers, MA).

The monoclonal antibody, PCL-2, was coupled to the activated Sepharose 4B as follows: 1 g (3.5 ml of gel) of cyanogen bromide activated Sepharose 4B (Pharmacia LKB Biotechnology, Piscataway, NJ) was swollen for 15 minutes in 1 mM HCl. The swollen gel was resuspended in 0.1 M NaHCO_3 , 0.5 M NaCl pH 8.3 and washed several times. The washed gel was resuspended in 11 ml of monoclonal antibody solution (PCL-2, 3.5 mg/ml in bicarbonate buffer pH 8.3) with a coupling ratio of approximately 10 mg/ml gel. Coupling was allowed to proceed for 2 h at room temperature on a rotary mixer, and the gel was recovered by gentle centrifugation. The monoclonal supernatant was removed and replaced by 1 M ethanolamine in order to block any remaining sites on the Sepharose. Blocking was performed overnight at 4°C. Excess adsorbed protein was removed by sequential acid and alkali washes (0.1 M acetate, 0.5 M NaCl pH 4.0; 0.1 M NaHCO_3 , 0.5 M NaCl pH 8.3), and the coupled gel was stored in 50 mM Tris-HCl, 150 mM NaCl pH 6.5, 0.02% azide.

30 Example 6

Samples of purified recombinant transgenic protein C were compared with plasma-derived protein C and a plasma-derived activated protein C (APC) preparations. Samples were run on SDS PAGE 4-20% acrylamide gradient gels under reducing conditions and silver stained for protein.

The plasma-derived material shows the presence of a heavy-chain doublet around 44 kDa (Figure 1, Lane 1). This has been reported to be due to partial occupancy of the three possible N-linked glycosylation sites on the molecule. A similar doublet, although of a slightly lower mass presumably due to some subtle change in glycosylation profile, has also been seen with the transgenic protein C. The light chain was visible around 22 kDa for both preparations. Significantly, in the case of the plasma-derived material uncleaved single-chain was clearly visible above the heavy chain doublet. Plasma-derived protein normally contained 5-10 percent of this inactive material. In contrast, the transgenic protein C contains no obvious single chain by this gel analysis. Therefore, it contains less than a few percent at most of inactive material. This most likely reflects the increased efficiency of cleavage of the modified inter-chain site. In further support of this observation no single chain was visible by direct western blot analysis of transgenic sheep milk (40387, expression level 300 µg/ml).

The purified transgenic protein C was further characterized as follows:

A. ELISA

An enzyme-linked immunosorbent assay (ELISA) for protein C was done as follows: Affinity-purified polyclonal antibody to human protein C (100 µl of 1 µg/ml in 0.1 M Na₂CO₃, pH 9.6) was added to each well of a 96-well microtiter plate, and the plates were incubated overnight at 4°C. The wells were then washed three times with phosphate buffered saline (PBS) containing 0.05% Tween-20 and incubated with 100 µl of 1% bovine serum albumin (BSA), 0.05% Tween-20 in PBS at 4°C overnight. The plates were then rinsed several times with PBS, air dried and stored at 4°C. To assay samples, 100 µl of each sample was incubated for 1 h at 37°C with a biotin-conjugated sheep polyclonal antibody to protein C (30 ng/ml) in PBS containing 1% BSA and 0.05% Tween-20. After incubation,

the wells were rinsed with PBS, and alkaline phosphatase activity was measured by the addition of 100 μ l of phosphatase substrate (Sigma, St. Louis, MO) in 10% diethanolamine, pH 9.8, containing 0.3 mM $MgCl_2$. The absorbance at 405 nm was read on a microtiter plate reader. Quantitation was by comparison with a standard curve using plasma-derived protein C quantitated by amino acid analysis.

10 B. Amino-Terminal Sequencing

Amino-terminal sequencing of the transgenic material was performed to ascertain the extent of prosequence removal and to evaluate the presence of gamma-carboxylation. There were three possible N-terminal sequences of protein C. These were: 1) Prosequence which directs gamma-carboxylation and could have remained on the light chain if the first cleavage site was incompletely processed, 2) the light chain and 3) the heavy chain. N-terminal sequencing of protein C obtained from transgenic milk should have contained only the latter two sequences if correct processing had occurred at both of the cleavage sites. Amino-terminal sequencing would have also been expected to reveal the presence of gamma-carboxylation in the light chain. There are nine sites of carboxylation in the first twenty-nine amino acids of the light chain. On an analysis of released amino acids, the PTH-gamma carboxylic acid derivatives eluted from the HPLC column in the break-through and could therefore be analyzed. Thus, a gamma carboxylic acid showed up on the amino-terminal sequence as a space rather than a glutamic acid.

The yields of amino acids in pmol released from the sequencing of approximately 27 pmol (1.4 μ l) of purified transgenic protein C corresponded well to those expected for an equimolar mixture of light and heavy chains, and no obvious sequence was discernible for the prosequence. Moreover, no other aberrant sequences were

detected, thus indicating a lack of inappropriate proteolytic cleavages.

As stated previously, gamma-carboxylated glutamate residues were expected to sequence as blanks using standard instrument conditions. However, sequencing protein C gives a double sequence which must be deconvoluted using knowledge of the expected light and heavy chain sequences. Normally, if the light chain alone were sequenced the gla residues at positions six and seven would appear as blanks. However when sequenced as intact protein C, the heavy chain sequence contains a glutamate residue at position six. Therefore, the only indirect confirmation of the presence of a gla residue in the light chain was the absence of glutamate at position seven which was not 'over written' by a glutamate in the heavy chain (Figure 2). Two other indirect confirmations of the presence of gamma carboxylation of the transgenic product are described below.

20 C. Mass Analysis of the Purified Light Chain

The protein sequence of the transgenic-derived protein C precursor had been modified with an Arg-Arg-Lys-Arg (SEQ ID NO: 20) cleavage site between the light and heavy chains to promote more efficient cleavage of the single chain to 2-chain form. Western blot analysis of the transgenic protein C milk and examination of the purified protein C on reducing gels had already confirmed that efficient cleavage had occurred. Normally during secretion, but after cleavage of the plasma-derived material, the two basic amino acids at the carboxy-terminus of the light chain are trimmed back by a basic carboxypeptidase. Establishing whether the carboxy-terminus of the transgenic protein C light chain had been processed to remove the two extra basic amino acids introduced by this modification, as well as the two natural ones, was achieved by measuring the mass of the purified light chain in a quadropole instrument using on-line liquid

chromatography and electro-spray ionization. In order to achieve this, all of the cysteine residues of protein C were reduced and alkylated, and then the two chains were separated by reversed-phase chromatography.

5

C1. Reductive Alkylation

Because protein C is heavily cross-linked for a molecule of approximately 52 kDa, with twelve disulfide bridges (17 of the 24 cysteines involved are in the light chain), it was necessary to reductively alkylate the entire protein before attempting to separate the chains by reversed-phase chromatography. In view of the large number of cysteines in the light chain, alkylation was done with iodoacetamide, in place of the more commonly used vinyl pyridine, to prevent the molecule from becoming excessively hydrophobic.

The transgenic protein C material (6 nmol of protein or 144 pmol of thiol) was reductively alkylated as follows: 0.5 mg of protein C (by ELISA) in 0.5 ml of TBS was added to 50 μ l of 1 M Tris pH 8.0, 450 μ l water, 570 mg guanidinium chloride, and 10 μ l at 50 mg/ml DTT (0.3 μ mol representing a 20 fold excess of added thiol over cysteine thiol. The mixture was incubated for 2 hours at 37°C. After incubation, 20 μ l at 120 mg/ml iodoacetamide (0.6 M representing a 2 fold excess over DTT on a molar basis) was added, and the mixture was incubated in the dark for one hour at 4°C. The reaction was quenched by adding 50 μ l at 50 mg/ml DTT representing a 2.5 fold excess over iodoacetamide. The sample (final volume 1.5 ml) was stored at -20°C until analysis.

30

D. Purification of the Light Chain

Purification of protein C light chain was achieved using a large pore polystyrene column with divinyl benzene interactive groups (PLRP-S, 4000Å, 8 μ m, 2.1 mm ID: Polymer Laboratories, Shropshire, UK). The optimum conditions for separation of the heavy and light

35

chains were determined to be: solvent A (0.1% TFA) and solvent B (100% acetonitrile) at a flow of 0.5 ml/min with a detector wavelength of 215 nm and a gradient of 30 to 60% solvent B over 60 min.

5 Fractions were collected across the eluted peaks, and samples (10 µl) were analyzed by SDS PAGE on 4-20% gradient acrylamide gels under non-reducing conditions. The light chain (fractions 3 to 5) was completely resolved from both the heavy chain (fractions 7 to 9) and a single fraction (6) which contained a mixture of heavy chain and what appeared to be unglycosylated light chain.

A sample containing fully resolved light chain was prepared for deglycosylation by centrifugal 15 evaporation under reduced pressure at room temperature. Deglycosylation was carried out using peptide N-glycanase (PNGase; Oxford Glycosystems, Oxford, UK). The protein sample was redissolved in 50 µl of buffer and incubated overnight with 1 unit (5 µl) PNGase, according to 20 manufacturer's specifications.

The light chain was purified from reduced and alkylated plasma-derived protein C by the same method and deglycosylated for further analysis.

25 E. Analysis by Mass Spectroscopy

Samples of purified light chain were subjected to mass analysis using a liquid chromatography - electrospray interface to a Sciex Quadropole Mass Analyser (Sciex/Perkin Elmer, Toronto, CA). The LC system used a 30 0.5 mm ID column packed with PLRP-S 4000Å, 8µm resin (Polymer Laboratories). The solvent system contained buffer A (0.1% formic acid), buffer B (0.1% formic acid and a 5:2 (v/v) mixture of ethanol to propan-1-ol). The gradient used was from 5-60% buffer B over 35 minutes at a 35 flow rate of 25 µl per minute. The outflow of the column was linked via a UV detector to the mass spectrometer which was run in positive-ion mode.

The purified and deglycosylated transgenic light chain was analyzed and gave a relatively weak spectrum which was reconstructed to give two components with masses of 18,911.0 and 18,971.0. The plasma light chain was also
5 analyzed and gave a stronger signal with a single major component. The spectrum of the plasma light chain was reconstructed to give a single mass of 18,970.0.

The predicted mass for the light chain carrying nine gamma-carboxy glutamic acids, one β -hydroxy aspartic
10 acid and seventeen carbamidomethyl cysteine residues and ending with Leu₁₅₅ was 18966.9723, which is very close to the masses detected for the transgenic (18,971.0) and plasma-derived (18,970.0) light chains. The small differences in mass were well within the accuracy
15 limitations for this instrument, particularly with the LC delivery. This shows that the mass of the redirectively-alkylated and deglycosylated transgenic light chain is essentially identical to that for the plasma-derived protein C. This implies that both molecules have
20 undergone the same post-translational modifications and that the transgenic material is fully gamma carboxylated, has had all four basic amino acids trimmed back from the carboxy-terminus of the light chain and has single β hydroxy-alanine.

25

F. Activity Measurements

The activity of the transgenic protein C was compared with that of the plasma-derived material in a coagulation assay. First each sample of protein C,
30 quantitated by amino acid composition analysis, was activated by incubation with Protac, a snake venom (American Diagnostica Inc, Greenwich, CT) at a venom to protein ratio of 1 Unit Protac: 10 μ g protein C for 60 minutes at 37°C. Aliquots of the activated material were
35 then compared for their ability to prolong the clotting time of protein C depleted human plasma (Diagnostic Reagents Ltd) in the presence of activated partial

thromboplastin time reagent - cephalin from rabbit brain (Sigma) and calcium using a mechanical coagulometer (Diagnostica Stago, Asmieres, FR). A comparison of clotting times with various additions of transgenic and plasma-derived protein C (Figure 3) shows that the two preparations had the same anti-coagulant activity per mg of protein.

In summary, results show that the sheep-derived transgenic protein C is correctly post-translationally processed, with respect to gamma-carboxylation and probably beta-hydroxylation, and has anticoagulant activity fully equivalent to a high quality purified plasma standard. The results demonstrate that the C-terminal processing of the light chain, with the modified RRKR cleavage site rather than the naturally occurring KR site, has the two extra basic amino acids removed along with the natural ones.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

25

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle
WA
USA
98102

PPL Therapeutics
Roslin
Edinburgh
Scotland
UK
EH25 9PP

(ii) TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC ANIMALS

(iii) NUMBER OF SEQUENCES: 25

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: ZymoGenetics, Inc.
(B) STREET: 1201 Eastlake Avenue East
(C) CITY: Seattle
(D) STATE: WA
(E) COUNTRY: USA
(F) ZIP: 98102

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0. Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Sawislak, Deborah A

(B) REGISTRATION NUMBER: 37,438
(C) REFERENCE/DOCKET NUMBER: 95-28PC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 206-442-6672
(B) TELEFAX: 206-442-6678

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11725 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: join(3520..3630, 5093..5117, 5210..5347, 5450
..5584, 8253..8395, 9269..9386, 10516..11102)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGTGAATCTG GGCGAGTAAC ACAAACTTG AGTGCCTTA CCTGAAAAAT AGAGGTTAGA	60
GGGATGCTAT GTGCCATTGT GTGTGTGTGT TGGGGGTGGG GATTGGGGGT GATTTGTGAG	120
CAATTGGAGG TGAGGGTGGG GCCCAGTGCC CAGCACCTAT GCACTGGGGA CCCAAAAAGG	180
AGCATCTTCT CATGATTTTA TGTATCAGAA ATTGGGATGG CATGTCATTG GGACAGCGTC	240
TTTTTCTTG TATGGTGGCA CATAAATACA TGTGTCTTAT AATTAATGGT ATTTTAGATT	300
TGACGAAATA TGGAATATTA CCTGTTGTGC TGATCTTGGG CAACTATAA TATCTCTGGG	360
CAAAAATGTC CCCATCTGAA AAACAGGGAC AACGTTCTC CCTCAGCCAG CCACTATGGG	420
GCTAAAATGA GACCACATCT GTCAAGGGTT TTGCCCTCAC CTCCCTCCCT GCTGGATGGC	480
ATCCTTGGTA GGCAGAGGTG GGCTTCGGGC AGAACAAGCC GTGCTGAGCT AGGACCAGGA	540

GTGCTAGTGC CACTGTTTGT CTATGGAGAG GGAGGCCTCA GTGCTGAGGG CCAAGCAAAAT	600
ATTTGTGGTT ATGGATTAAC TCGAACTCCA GGCTGTCATG GCGGCAGGAC GGCGAACTTG	660
CAGTATCTCC ACGACCCGCC CCTGTGAGTC CCCCTCCAGG CAGGTCTATG AGGGGTGTGG	720
AGGGAGGGCT GCCCCCGGGA GAAGAGAGCT AGGTGGTGAT GAGGGCTGAA TCCTCCAGCC	780
AGGGTGCTCA ACAAGCCTGA GCTTGGGGTA AAAGGACACA AGGCCCTCCA CAGGCCAGGC	840
CTGGCAGCCA CAGTCTCAGG TCCCTTTGCC ATGCGCCTCC CTCTTTCCAG GCCAAGGTC	900
CCCAGGCCCA GGGCCATTCC AACAGACAGT TTGGAGCCCA GGACCCTCCA TTCTCCCCAC	960
CCCACTTCCA CCTTTGGGGG TGTCGGATTT GAACAAATCT CAGAAGCGGC CTCAGAGGGA	1020
GTCGGCAAGA ATGGAGAGCA GGGTCCGGTA GGGTGTGCAG AGGCCACGTG GCCTATCCAC	1080
TGGGGAGGGT TCCTTGATCT CTGGCCACCA GGGCTATCTC TGTGGCCTTT TGGAGCAACC	1140
TGGTGGTTTG GGGCAGGGGT TGAATTTCCA GGCCTAAAC CACACAGGCC TGGCCTTGAG	1200
TCCTGGCTCT GCGAGTAATG CATGGATGTA AACATGGAGA CCCAGGACCT TGCCTCAGTC	1260
TTCCGAGTCT GGTGCCTGCA GTGTACTGAT GGTGTGAGAC CCTACTCCTG GAGGATGGGG	1320
GACAGAATCT GATCGATCCC CTGGGTTGGT GACTTCCCTG TGCAATCAAC GGAGACCAGC	1380
AAGGGTTGGA TTTTAAATAA ACCACTTAAC TCCTCCGAGT CTCAGTTTCC CCCTCTATGA	1440
AATGGGGTTG ACAGCATTAA TAACTACCTC TTGGGTGGTT GTGAGCCTTA ACTGAAATCA	1500
TAATATCTCA TGTTTACTGA GCATGAGCTA TGTGCAAAGC CTGTTTTGAG AGCTTTATGT	1560
GGACTAACTC CTTTAATTCT CACAACACCC TTAAAGGCAC AGATACACCA CGTTATTCCA	1620
TCCATTTTAC AAATGAGGAA ACTGAGGCAT GGAGCAGTTA AGCATCTTGC CCAACATTGC	1680
CCTCCAGTAA GTGCTGGAGC TGGAAATTGC ACCGTGCAGT CTGGCTTCAT GGCCTGCTCT	1740
GTGAATCCTG TAAAAATTGT TTGAAAGACA CCATGAGTGT CCAATCAACG TTAGCTAATA	1800
TTCTCAGCCC AGTCATCAGA CCGGCAGAGG CAGCCACCCC ACTGTCCCCA GGGAGGACAC	1860
AAACATCCTG GCACCCTCTC CACTGCATTC TGGAGCTGCT TTCTAGGCAG GCAGTGTGAG	1920

CTCAGCCCCA CGTAGAGCGG GCAGCCGAGG CCTTCTGAGG CTATGTCTCT AGCGAACAAG	1980
GACCCCTCAAT TCCAGCTTCC GCCTGACGGC CAGCACACAG GGACAGCCCT TTCATTCCGC	2040
TTCCACCTGG GGGTGCAGGC AGAGCAGCAG CGGGGGTAGC ACTGCCCGBA GCTCAGAAGT	2100
CCTCCTCAGA CAGGTGCCAG TGCCTCCAGA ATGTGGCAGC TCACAAGCCT CCTGCTGTTC	2160
GTGGCCACCT GGGGAATTTT CGGCACACCA GCTCCTCTTG GTAAGGCCAC CCCACCCCTA	2220
CCCCGGGACC CTTGTGGCCT CTACAAGGCC CTGGTGGCAT CTGCCCAGGC CTTACAGCT	2280
TCCACCATCT CTCTGAGCCC TGGGTGAGGT GAGGGGCAGA TGGGAATGGC AGGAATCAAC	2340
TGACAAGTCC CAGGTAGGCC AGCTGCCAGA GTGCCACACA GGGGCTGCCA GGGCAGGCAT	2400
GCGTGATGGC AGGGAGCCCC GCGATGACCT CCTAAAGCTC CCTCCTCCAC ACGGGGATGG	2460
TCACAGAGTC CCCTGGGCCT TCCCTCTCCA CCCACTCACT CCCTCAACTG TGAAGACCCC	2520
AGGCCCAGGC TACCGTCCAC ACTATCCAGC ACAGCCTCCC CTACTCAAAT GCACACTGGC	2580
CTCATGGCTG CCCTGCCCCA ACCCCTTTCC TGGTCTCCAC AGCCAACGGG AGGAGGCCAT	2640
GATTCTTGGG GAGGTCCGCA GGCACATGGG CCCCTAAAGC CACACCAGGC TGTGTTTTC	2700
ATTTGTGCCT TTATAGAGCT GTTTATCTGC TTGGGACCTG CACCTCCACC CTTTCCCAAG	2760
GTGCCCTCAG CTCAGGCATA CCCTCCTCTA GGATGCCTTT TCCCCATCC CTTCTTGCTC	2820
ACACCCCCAA CTTGATCTCT CCCTCCTAAC TGTGCCCTGC ACCAAGACAG ACACTTCACA	2880
GAGCCCAGGA CACACCTGGG GACCCTTCCT GGGTGATAGG TCTGTCTATC CTCCAGGTGT	2940
CCCTGCCCCA GGGGAGAAGC ATGGGGAATA CTTGGTTGGG GGAGGAAAGG AAGACTGGGG	3000
GGATGTGTCA AGATGGGGCT GCATGTGGTG TACTGGCAGA AGAGTGAGAG GATTTAACCT	3060
GGCAGCCTTT ACAGCAGCAG CCAGGGCTTG AGTACTTATC TCTGGGCCAG GCTGTATTGG	3120
ATGTTTTACA TGACGGTCTC ATCCCCATGT TTTTGGATGA GTAAATTGAA CCTTAGAAAG	3180
GTAAAGACAC TGGCTCAAGG TCACACAGAG ATCGGGGTGG GGTTCACAGG GAGGCCTGTC	3240

CATCTCAGAG CAAGGCTTCG TCCTCCAACT GCCATCTGCT TCCTGGGGAG GAAA/GAGCA	3300
GAGGACCCCT GCGCCAAGCC ATGACCTAGA ATTAGAATGA GTCTTGAGGG GCGCAGACA	3360
AGACCTTCCC AGGCTCTCCC AGCTCTGCTT CCTCAGACCC CCTCATGGCC CCAGCCCTC	3420
TTAGGCCCCT CACCAAGGTG AGCTCCCCTC CCTCCAAAAC CAGACTCAGT GTTCTCCAGC	3480
AGCGAGCGTG CCCACCAGGT GCTGCGGATC CGCAAACGT GCC AAC TCC TTC CTG	3534
GAG GAG CTC CGT CAC AGC AGC CTG GAG CGG GAG TGC ATA GAG GAG ATC	3582
TGT GAC TTC GAG GAG GCC AAG GAA ATT TTC CAA AAT GTG GAT GAC ACA	3630
GTAAGGCCAC CATGGGTCCA GAGGATGAGG CTCAGGGGCG AGCTGGTAAC CAGCAGGGGC	3690
CTCGAGGAGC AGGTGGGGAC TCAATGCTGA GGCCCTCTTA GGAGTTGTGG GGGTGGCTGA	3750
GTGGAGCGAT TAGGATGCTG GCCCTATGAT GTCGGCCAGG CACATGTGAC TGCAAGAAAC	3810
AGAATTCAGG AAGAAGCTCC AGGAAAGAGT GTGGGGTGAC CCTAGGTGGG GACTCCCACA	3870
GCCACAGTGT AGGTGGTTCA GTCCACCCTC CAGCCACTGC TGAGCACCAC TGCTCCCCG	3930
TCCCACCTCA CAAAGAGGGG ACCTAAAGAC CACCCTGCTT CCACCCATGC CTCTGCTGAT	3990
CAGGGTGTGT GTGTGACCGA AACTCACTTC TGTCCACATA AAATCGCTCA CTCTGTGCCT	4050
CACATCAAAG GGAGAAAATC TGATTGTTCA GGGGGTCGGA AGACAGGGTC TGTGTCTAT	4110
TTGTCTAAGG GTCAGAGTCC TTTGGAGCCC CCAGAGTCCT GTGGACGTGG CCCTAGGTAG	4170
TAGGGTGAGC TTGGTAACGG GGCTGGCTTC CTGAGACAAG GCTCAGACCC GCTCTCTCCC	4230
TGGGGATCGC TTCAGCCACC AGGACCTGAA AATTGTGCAC GCCTGGGCCC CCTTCAAGG	4290
CATCCAGGGA TGCTTTCCAG TGGAGGCTTT CAGGGCAGGA GACCCTCTGG CCTGCACCCT	4350
CTCTTGCCCT CAGCCTCCAC CTCCTTGACT GGACCCCAT CTGGACCTCC ATCCCAACCA	4410
CCTCTTTCCC CAGTGGCCTC CCTGGCAGAC ACCACAGTGA CTTTCTGCAG GCACATATCT	4470
GATCACATCA AGTCCCCACC GTGCTCCCAC CTCACCATG GTCTCTCAGC CCCAGCAGCC	4530
TTGGCTGGCC TCTCTGATGG AGCAGGCATC AGGCACAGGC CGTGGGTCTC AACGTGGGCT	4590

GGGTGGTCCT GGACCAGCAG CAGCCGCCGC AGCAGCAACC CTGGTACCTG GTTAGGAACG 4650
CAGACCCCTCT GCCCCATCC TCCCAACTCT GAAAAAACT GGCTTAGGGA AAGGCGCGAT 4710
GCTCAGGGGT CCCCCAAAGC CCGCAGGCAG AGGGAGTGAT GGGACTGGAA GGAGGCCGAG 4770
TGA CT TGGTG AGGGATTCTGG GTCCCTTGCA TGCAGAGGCT GCTGTGGGAG CGGACAGTCG 4830
CGAGAGCAGC ACTGCAGCTG CATGGGGAGA GGGTGTTGCT CCAGGGACGT GGGATGGAGG 4890
CTGGGCGCGG GCGGGTGGCG CTGGAGGGCG GGGGAGGGG AGGGAGCACC AGCTCCTAGC 4950
AGCCAACGAC CATCGGGCGT CGATCCCTGT TTGTCTGGAA GCCCTCCCCT CCCCTGCCCCG 5010
CTCACCCGCT GCCCTGCCCC ACCCGGGCGC GCCCTCCGC ACACGGCTG CAGGAGCCTG 5070
ACGCTGCCCCG CTCTCTCCGC AG CTG GCC TTC TGG TCC AAG CAC GTC G 5117
GTGAGTGCGT TCTAGATCCC CGGCTGGACT ACCGGCGCCC GCGCCCTCG GGATCTCTGG 5177
CCGCTGACCC CCTACCCCGC CTTGTGTCGC AG AC GGT GAC CAG TGC TTG GTC 5229
TTG CCC TTG GAG CAC CCG TGC GCC AGC CTG TGC TGC GGG CAC GGC ACG 5277
TGC ATC GAC GGC ATC GGC AGC TTC AGC TGC GAC TGC CGC AGC GGC TGG 5325
GAG GGC CGC TTC TGC CAG CGC G GTGAGGGGGA GAGGTGGATG CTGGCGGGCG 5377
GCGGGGCGGG GCTGGGGCCG GGTGGGGGC GCGGCACCAG CACCAGCTGC CCGCGCCCTC 5437
CCCTGCCCCG AG AG GTG AGC TTC CTC AAT TGC TCT CTG GAC AAC GGC 5484
GGC TGC ACG CAT TAC TGC CTA GAG GAG GTG GGC TGG CGG CGC TGT AGC 5532
TGT GCG CCT GGC TAC AAG CTG GGG GAC GAC CTC CTG CAG TGT CAC CCC 5580
GCA G GTGAGAAGCC CCAATACAT CGCCCAGGAA TCACGCTGGG TCGGGGTGG 5634
GCAGGCCCT GACGGGCGCG GCGCGGGGG CTCAGGAGG TTTCTAGGGA GGGAGCGAGG 5694
AACAGAGTTG AGCCTTGGGG CAGCGGCAGA CGCGCCCAAC ACCGGGGCCA CTGTTAGCGC 5754
AATCAGCCCG GGAGCTGGGC GCGCCCTCCG CTTTCCCTGC TTCCTTTCTT CCTGGCGTCC 5814

CCGCTTCCTC CGGGCGCCCC TGCACCTGG GGCCACCTCC TGGAGCGCAA GCCCASTGGT	5874
GGCTCCGCTC CCCAGTCTGA GCGTATCTGG GGCAGGGCGT GCAGCGTCCT CCTCCATGTA	5934
GCCTGGCTGC GTTTTCTCT GACGTTGTCC GGCCTGCATC GCATTTCCCT CTTTACCCCC	5994
TTGCTTCCTT GAGGAGAGAA CAGAATCCCG ATTCTGCCTT CTTCTATATT TTCCTTTTAA	6054
TGCATTTTAA TCAAATTTAT ATATGTATGA AACTTTAAAA ATCAGAGTTT TACAACTCTT	6114
ACACTTTCAG CATGCTGTTT CTTGGCATGG GTCCTTTTTT CATTCAATTT CATAAAGGT	6174
GGACCCTTTT AATGTGGAAA TTCCTATCTT CTGCCTCTAG GGCATTTATC ACTTAATTCT	6234
TCTACAATCT CCCCTTTACT TCCTCTATTT TCTCTTCTG GACCTCCCAT TATTCAGACC	6294
TCTTTCCTCT AGTTTATTG TCTCTTCTAT TTCCCATCTC TTGACTTTG TGTTCCTT	6354
CAGGGAACCT TCTTTTTTTT CTTTTTTTTT GAGATGGAGT TTCACTCTTG TTGTCCAGG	6414
CTGGAGTGCA ATGACGTGAT CTCAGCTCAC CACAACCTCC GCCTCCTGGA TTCAAGCGAT	6474
TCTCCTGCCG CAGCCTCCCG AGTAGCTGGG ATTACAGGCA TGCGCCACCA CGCCCAGCTA	6534
ATTTTGTGTT TTTAGTAGAG AAGGGGTTT TCCGTGTTGG TCAAGCTGGT CTTGAACTCC	6594
TGACCTCAGG TGATCCACCT GCCTTGGCCT CCTAAAGTGC TGGGATTACA GGCCTGAGCC	6654
ACCGCGCCCA GCCTCTTCA GGGAACCTTC TACAACTTTA TAATTCAATT CTTCTGCAGA	6714
AAAAAATTTT TGGCCAGGCT CAGTAGCTCA GACCAATAAT TCCAGCACTT TGAGAGGCTG	6774
AGGTGGGAGG ATTGCTTGAG CTTGGGAGTT TGAGACTAGC CTGGGCAACA CAGTGAGACC	6834
CTGTCTCTAT TTTTAAAAAA AGTAAAAAAA GATCTAAAAA TTAACTTTT TATTTTGAAA	6894
TAATTAGATA TTTCCAGGAA GCTGCAAAGA AATGCCTGGT GGGCCTGTTG GCTGTGGTT	6954
TCCTGCAAGG CCGTGGGAAG GCCCTGTCAT TGGCAGAACC CCAGATCGTG AGGGCTTTCC	7014
TTTTAGGCTG CTTTCTAAGA GGA CTCTCC AAGCTCTTGG AGGATGGAAG ACGCTACCC	7074
ATGGTGTTCG GCCCCTCAGA GCAGGGTGGG GCAGGGGAGC TGGTGCCTGT GCAGGCTGTG	7134
GACATTTGCA TGA CTCCCTG TGGTCAGCTA AGAGCACCAC TCCTTCCTGA AGCGGGCCT	7194

GAAGTCCCTA GTCAGAGCCT CTGGTTCACC TTCTGCAGGC AGGGAGAGGG GAGTCAAGTC 7254
AGTGAGGAGG GCTTTCGCAG TTCTCTTAC AAACCTCTCAA CATGCCCTCC CACCTGCACT 7314
GCCTTCCTGG AAGCCCCACA GCCTCCTATG GTTCCGTGGT CCAGTCCTTC AGCTTCTGGG 7374
CGCCCCATC ACGGGCTGAG ATTTTGTCTT TCCAGTCTGC CAAGTCAGTT ACTGTGTCCA 7434
TCCATCTGCT GTCAGCTTCT GGAATTGTTG CTGTTGTGCC CTTTCCATTC TTTTGTATG 7494
ATGCAGCTCC CCTGCTGACG ACGTCCCATT GCTCTTTTAA GTCTAGATAT CTGGACTGGG 7554
CATTCAAGGC CCATTTTGAG CAGAGTCGGG CTGACCTTTC AGCCCTCAGT TCTCCATGGA 7614
GTATGCGCTC TCTTCTTGGC AGGGAGGCCT CACAAACATG CCATGCCTAT TGTAGCAGCT 7674
CTCCAAGAAT GCTCACCTCC TTCTCCCTGT AATTCCTTTC CTCTGTGAGG AGCTCAGCAG 7734
CATCCCATTA TGAGACCTTA CTAATCCCAG GGATCACCCC CAACAGCCCT GGGGTACAAT 7794
GAGCTTTTAA GAAGTTTAA CACCTATGTA AGGAGACACA GGCAGTGGGC GATGCTGCCT 7854
GGCCTGACTC TTGCCATTGG GTGGTACTGT TTGTTGACTG ACTGACTGAC TGA CTGGAGG 7914
GGGTTTGTA TTTGTATCTC AGGGATTACC CCCAACAGCC CTGGGGTACA ATGAGCCTTC 7974
AAGAAGTTTA ACAACCTATG TAAGGACACA CAGCCAGTGG GTGATGCTGC CTGGTCTGAC 8034
TCTTGCCATT CAGTGGCACT GTTTGTTGAC TGA CTGACTG ACTGACTGGC TGA CTGGAGG 8094
GGGTTTCATAG CTAATATTAA TGGAGTGGTC TAAGTATCAT TGGTTCCTTG AACCTGCAC 8154
TGTGGCAAAG TGGCCACAG GCTGGAGGAG GACCAAGACA GGAGGGCAGT CTCGGGAGGA 8214
GTGCCTGGCA GGCCCTCAC CACCTCTGCC TACCTCAG TG AAG TTC CCT TGT 8266
GGG AGG CCC TGG AAG CGG ATG GAG AAG AAG CGC AGT CAC CTG AAA CGA 8314
GAC ACA GAA GAC CAA GAA GAC CAA GTA GAT CCG CGG CTC ATT GAT GGG 8362
AAG ATG ACC AGG CGG GGA GAC AGC CCC TGG CAG GTGGGAGGCG AGGCAGCACC 8415
GGCTCGTCAC GTGCTGGGTC CGGGATCACT GAGTCCATCC TGGCAGCTAT GCTCAGGGTG 8475

CAGAAACCGA GAGGGAAGCG CTGCCATTGC GTTTGGGGGA TGATGAAGGT GGGGGA.TGCT	8535
TCAGGGAAAG ATGGACGCAA CCTGAGGGGA GAGGAGCAGC CAGGGTGGGT GAGGGGAGGG	8595
GCATGGGGGC ATGGAGGGGT CTGCAGGAGG GAGGGTTACA GTTTCTAAAA AGAGCTGGAA	8655
AGACACTGCT CTGCTGGCGG GATTTTAGGC AGAAGCCCTG CTGATGGGAG AGGGCTAGGA	8715
GGGAGGGCCG GGCCTGAGTA CCCCTCCAGC CTCCACATGG GAACTGACAC TTA CTGGGT	8775
CCCCTCTCTG CCAGGCATGG GGGAGATAGG AACCAACAAG TGGGAGTATT TGCCCTGGGG	8835
ACTCAGACTC TGCAAGGGTC AGGACCCCAA AGACCCGGCA GCCCAGTGGG ACCACAGCCA	8895
GGACGGCCCT TCAAGATAGG GGCTGAGGGA GGCCAAGGGG AACATCCAGG CAGCCTGGGG	8955
GCCACAAAGT CTTCTGGAA GACACAAGGC CTGCCAAGCC TCTAAGGATG AGAGGAGCTC	9015
GCTGGGCGAT GTTGGTGTGG CTGAGGGTGA CTGAAACAGT ATGAACAGTG CAGGAACAGC	9075
ATGGGCAAAG GCAGGAAGAC ACCCTGGGAC AGGCTGACAC TGTAAAATGG GCAAAAATAG	9135
AAAACGCCAG AAAGGCCTAA GCCTATGCCC ATATGACCAG GGAACCCAGG AAAGTGCATA	9195
TGAAACCCAG GTGCCCTGGA CTGGAGGCTG TCAGGAGGCA GCCCTGTGAT GTCATCATCC	9255
CACCCCATTC CAG GTG GTC CTG CTG GAC TCA AAG AAG AAG CTG GCC TGC	9304
GGG GCA GTG CTC ATC CAC CCC TCC TGG GTG CTG ACA GCG GCC CAC TCC	9352
ATG GAT GAG TCC AAG AAG CTC CTT GTC AGG CTT G GTATGGGCTG	9396
GAGCCAGGCA GAAGGGGGCT GCCAGAGGCC TGGGTAGGGG GACCAGGCAG GCTGTTT CAGG	9456
TTTGGGGGAC CCCGCTCCCC AGGTGCTTAA GCAAGAGGCT TCTTGAGCTC CACAGAAGGT	9516
GTTTGGGGGG AAGAGGCCTA TGTGCCCCCA CCCTGCCCAC CCATGTACAC CCAGTATTTT	9576
GCAGTAGGGG GTTCTCTGGT GCCCTCTTCG AATCTGGGCA CAGGTACCTG CACACATATG	9636
TTTGTGAGGG GCTACACAGA CCTTCACCTC TCCACTCCCA CTCATGAGGA GCAGGCTGTG	9696
TGGGCCTCAG CACCCTTGGG TGCAGAGACC AGCAAGGCCT GGCCTCAGGG CTGTGCCTCC	9756
CACAGACTGA CAGGGATGGA GCTGTACAGA GGGAGCCCTA GCATCTGCCA AAGCCACAAG	9816

CTGCTTCCT AGCAGGCTGG GGGCTCCTAT GCATTGGCCC CGATCTATGG CAATTTCTGG 9876
AGGGGGGGTC TGGCTCAACT CTTTATGCCA AAAAGAAGGC AAAGCATATT GAGAAAGGCC 9936
AAATTCACAT TTCCTACAGC ATAATCTATG CCAGTGGCCC CGTGGGGCTT GGCTTAGAAT 9996
TCCCAGGTGC TCTTCCCAGG GAACCATCAG TCTGGACTGA GAGGACCTTC TCTCTCAGGT 10056
GGGACCCGGC CCTGTCCTCC CTGGCAGTGC CGTGTTCCTGG GGGTCCTCCT CTCTGGGTCT 10116
CACTGCCCCT GGGGTCTCTC CAGCTACCTT TGCTCCATGT TCCTTTGTGG CTCTGGTCTG 10176
TGTCTGGGGT TTCCAGGGGT CTCGGGCTTC CCTGCTGCCC ATTCCTTCTC TGGTCTCAGG 10236
GCTCCGTGAC TCCTGAAAAC CAACCAGCAT CCTACCCCTT TGGATTGACA CCTGTTGGCC 10296
ACTCCTTCTG GCAGGAAAAG TCACCGTTGA TAGGGTTCCA CGGCATAGAC AGGTGGCTCC 10356
GCGCCAGTGC CTGGGACGTG TGGGTGCACA GTCTCCGGGT GAACCTTCTT CAGGCCCTCT 10416
CCCAGGCCTG CAGGGGCACA GCAGTGGGTG GGCCTCAGGA AAGTGCCACT GGGGAGAGGC 10476
TCCCCGCAGC CCACTCTGAC TGTGCCCTCT GCCCTGCAG GA GAG TAT GAC CTG 10529
CGG CGC TGG GAG AAG TGG GAG CTG GAC CTG GAC ATC AAG GAG GTC TTC 10577
GTC CAC CCC AAC TAC AGC AAG AGC ACC ACC GAC AAT GAC ATC GCA CTG 10625
CTG CAC CTG GCC CAG CCC GCC ACC CTC TCG CAG ACC ATA GTG CCC ATC 10673
TGC CTC CCG GAC AGC GGC CTT GCA GAG CGC GAG CTC AAT CAG GCC GGC 10721
CAG GAG ACC CTC GTG ACG GGC TGG GGC TAC CAC AGC AGC CGA GAG AAG 10769
GAG GCC AAG AGA AAC CGC ACC TTC GTC CTC AAC TTC ATC AAG ATT CCC 10817
GTG GTC CCG CAC AAT GAG TGC AGC GAG GTC ATG AGC AAC ATG GTG TCT 10865
GAG AAC ATG CTG TGT GCG GGC ATC CTC GGG GAC CGG CAG GAT GCC TGC 10913
GAG GGC GAC AGT GGG GGG CCC ATG GTC GCC TCC TTC CAC GGC ACC TGG 10961
TTC CTG GTG GGC CTG GTG AGC TGG GGT GAG GGC TGT GGG CTC CTT CAC 11009

AAC TAC GGC GTT TAC ACC AAA GTC AGC CGC TAC CTC GAC TGG ATC CAT 11057
 GGG CAC ATC AGA GAC AAG GAA GCC CCC CAG AAG AGC TGG GCA CCT 11102
 TAGCGACCCT CCCTGCAGGG CTGGGCTTTT GCATGGCAAT GGATGGGACA TTAAGGGAC 11162
 ATGTAACAAG CACACCGGCC TGCTGTTCTG TCCTTCCATC CCTCTTTTGG GCTCTTCTGG 11222
 AGGGAAGTAA CATTTACTGA GCACCTGTTG TATGTCACAT GCCTTATGAA TAGAATCTTA 11282
 ACTCCTAGAG CAACTCTGTG GGGTGGGGAG GAGCAGATCC AAGTTTTGCG GGGTCTAAAG 11342
 CTGTGTGTGT TGAGGGGGAT ACTCTGTTTA TGAAAAAGAA TAAAAACAC AACCACGAAG 11402
 CCACTAGAGC CTTTTCCAGG GCTTTGGGAA GAGCCTGTGC AAGCCGGGGA TGCTGAGGT 11462
 GAGGCTTGAC CAGCTTTCCA GCTAGCCCAG CTATGAGGTA GACATGTTTA GCTCATATCA 11522
 CAGAGGAGGA AACTGAGGGG TCTGAAAGGT TTACATGGTG GAGCCAGGAT TCAAACTAG 11582
 GTCTGACTCC AAAACCCAGG TGCTTTTTTC TGTTCTCCAC TGTCTGGAG GACAGCTGTT 11642
 TCGACGGTGC TCAGTGTGGA GGCCACTATT AGCTCTGTAG GGAAGCAGCC AGAGACCCAG 11702
 AAAGTGTGG TTCAGCCCAG AAT 11725

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 460 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Trp Gln Leu Thr Ser Leu Leu Leu Phe Val Ala Thr Trp Gly Ile
 1 5 10 15
 Ser Gly Thr Pro Ala Pro Leu Asp Ser Val Phe Ser Ser Ser Glu Arg
 20 25 30

Trp Glu Lys Trp Glu Leu Asp Leu Asp Ile Lys Glu Val Phe Val His
 275 280 285
 Pro Asn Tyr Ser Lys Ser Thr Thr Asp Asn Asp Ile Ala Leu Leu His
 290 295 300
 Leu Ala Gln Pro Ala Thr Leu Ser Gln Thr Ile Val Pro Ile Cys Leu
 305 310 315 320
 Pro Asp Ser Gly Leu Ala Glu Arg Glu Leu Asn Gln Ala Gly Gln Glu
 325 330 335
 Thr Leu Val Thr Gly Trp Gly Tyr His Ser Ser Arg Glu Lys Glu Ala
 340 345 350
 Lys Arg Asn Arg Thr Phe Val Leu Asn Phe Ile Lys Ile Pro Val Val
 355 360 365
 Pro His Asn Glu Cys Ser Glu Val Met Ser Asn Met Val Ser Glu Asn
 370 375 380
 Met Leu Cys Ala Gly Ile Leu Gly Asp Arg Gln Asp Ala Cys Glu Gly
 385 390 395 400
 Asp Ser Gly Gly Pro Met Val Ala Ser Phe His Gly Thr Trp Phe Leu
 405 410 415
 Val Gly Leu Val Ser Trp Gly Glu Gly Cys Gly Leu Leu His Asn Tyr
 420 425 430
 Gly Val Tyr Thr Lys Val Ser Arg Tyr Leu Asp Trp Ile His Gly His
 435 440 445
 Ile Arg Asp Lys Glu Ala Pro Gln Lys Ser Trp Ala
 450 455 460

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1386 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1380

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG TGG CAG CTC ACA AGC CTC CTG CTG TTC GTG GCC ACC TGG GGA ATT	48
Met Trp Gln Leu Thr Ser Leu Leu Leu Phe Val Ala Thr Trp Gly Ile	
1 5 10 15	
TCC GGC ACA CCA GCT CCT CTT GAC TCA GTG TTC TCC AGC AGC GAG CGT	96
Ser Gly Thr Pro Ala Pro Leu Asp Ser Val Phe Ser Ser Ser Glu Arg	
20 25 30	
GCC CAC CAG GTG CTG CGG ATC CGC AAA CGT GCC AAC TCC TTC CTG GAG	144
Ala His Gln Val Leu Arg Ile Arg Lys Arg Ala Asn Ser Phe Leu Glu	
35 40 45	
GAG CTC CGT CAC AGC AGC CTG GAG CGG GAG TGC ATA GAG GAG ATC TGT	192
Glu Leu Arg His Ser Ser Leu Glu Arg Glu Cys Ile Glu Glu Ile Cys	
50 55 60	
GAC TTC GAG GAG GCC AAG GAA ATT TTC CAA AAT GTG GAT GAC ACA CTG	240
Asp Phe Glu Glu Ala Lys Glu Ile Phe Gln Asn Val Asp Asp Thr Leu	
65 70 75 80	
GCC TTC TGG TCC AAG CAC GTC GAC GGT GAC CAG TGC TTG GTC TTG CCC	288
Ala Phe Trp Ser Lys His Val Asp Gly Asp Gln Cys Leu Val Leu Pro	
85 90 95	
TTG GAG CAC CCG TGC GCC AGC CTG TGC TGC GGG CAC GGC ACG TGC ATC	336
Leu Glu His Pro Cys Ala Ser Leu Cys Cys Gly His Gly Thr Cys Ile	
100 105 110	
GAC GGC ATC GGC AGC TTC AGC TGC GAC TGC CGC AGC GGC TGG GAG GGC	384
Asp Gly Ile Gly Ser Phe Ser Cys Asp Cys Arg Ser Gly Trp Glu Gly	
115 120 125	
CGC TTC TGC CAG CGC GAG GTG AGC TTC CTC AAT TGC TCT CTG GAC AAC	432
Arg Phe Cys Gln Arg Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn	
130 135 140	

GGC GGC TGC ACG CAT TAC TGC CTA GAG GAG GTG GGC TGG CGG CGC TGT Gly Gly Cys Thr His Tyr Cys Leu Glu Glu Val Gly Trp Arg Arg Cys 145 150 155 160	480
AGC TGT GCG CCT GGC TAC AAG CTG GGG GAC GAC CTC CTG CAG TGT CAC Ser Cys Ala Pro Gly Tyr Lys Leu Gly Asp Asp Leu Leu Gln Cys His 165 170 175	528
CCC GCA GTG AAG TTC CCT TGT GGG AGG CCC TGG AAG CGG ATG GAG AAG Pro Ala Val Lys Phe Pro Cys Gly Arg Pro Trp Lys Arg Met Glu Lys 180 185 190	576
AAG CGC AGT CAC CTG AAA CGA GAC ACA GAA GAC CAA GAA GAC CAA GTA Lys Arg Ser His Leu Lys Arg Asp Thr Glu Asp Gln Glu Asp Gln Val 195 200 205	624
GAT CCG CGG CTC ATT GAT GGG AAG ATG ACC AGG CGG GGA GAC AGC CCC Asp Pro Arg Leu Ile Asp Gly Lys Met Thr Arg Arg Gly Asp Ser Pro 210 215 220	672
TGG CAG GTG GTC CTG CTG GAC TCA AAG AAG AAG CTG GCC TGC GGG GCA Trp Gln Val Val Leu Leu Asp Ser Lys Lys Lys Leu Ala Cys Gly Ala 225 230 235 240	720
GTG CTC ATC CAC CCC TCC TGG GTG CTG ACA GCG GCC CAC TGC ATG CAT Val Leu Ile His Pro Ser Trp Val Leu Thr Ala Ala His Cys Met Asp 245 250 255	768
GAG TCC AAG AAG CTC CTT GTC AGG CTT GGA GAG TAT GAC CTG CGG CGC Glu Ser Lys Lys Leu Leu Val Arg Leu Gly Glu Tyr Asp Leu Arg Arg 260 265 270	816
TGG GAG AAG TGG GAG CTG GAC CTG GAC ATC AAG GAG GTC TTC GTC CAC Trp Glu Lys Trp Glu Leu Asp Leu Asp Ile Lys Glu Val Phe Val His 275 280 285	864
CCC AAC TAC AGC AAG AGC ACC ACC GAC AAT GAC ATC GCA CTG CTG CAC Pro Asn Tyr Ser Lys Ser Thr Thr Asp Asn Asp Ile Ala Leu Leu His 290 295 300	912
CTG GCC CAG CCC GCC ACC CTC TCG CAG ACC ATA GTG CCC ATC TGC CTC Leu Ala Gln Pro Ala Thr Leu Ser Gln Thr Ile Val Pro Ile Cys Leu 305 310 315 320	960

CCG GAC AGC GGC CTT GCA GAG CGC GAG CTC AAT CAG GCC GGC CAG GAG Pro Asp Ser Gly Leu Ala Glu Arg Glu Leu Asn Gln Ala Gly Gln Glu 325 330 335	1008
ACC CTC GTG ACG GGC TGG GGC TAC CAC AGC AGC CGA GAG AAG GAG GCC Thr Leu Val Thr Gly Trp Gly Tyr His Ser Ser Arg Glu Lys Glu Ala 340 345 350	1056
AAG AGA AAC CGC ACC TTC GTC CTC AAC TTC ATC AAG ATT CCC GTG GTC Lys Arg Asn Arg Thr Phe Val Leu Asn Phe Ile Lys Ile Pro Val Val 355 360 365	1104
CCG CAC AAT GAG TGC AGC GAG GTC ATG AGC AAC ATG GTG TCT GAG AAC Pro His Asn Glu Cys Ser Glu Val Met Ser Asn Met Val Ser Glu Asn 370 375 380	1152
ATG CTG TGT GCG GGC ATC CTC GGG GAC CGG CAG GAT GCC TGC GAG GGC Met Leu Cys Ala Gly Ile Leu Gly Asp Arg Gln Asp Ala Cys Glu Gly 385 390 395 400	1200
GAC AGT GGG GGG CCC ATG GTC GCC TCC TTC CAC GGC ACC TGG TTC CTG Asp Ser Gly Gly Pro Met Val Ala Ser Phe His Gly Thr Trp Phe Leu 405 410 415	1248
GTG GGC CTG GTG AGC TGG GGT GAG GGC TGT GGG CTC CTT CAC AAC TAC Val Gly Leu Val Ser Trp Gly Glu Gly Cys Gly Leu Leu His Asn Tyr 420 425 430	1296
GGC GTT TAC ACC AAA GTC AGC CGC TAC CTC GAC TGG ATC CAT GGG CAC Gly Val Tyr Thr Lys Val Ser Arg Tyr Leu Asp Trp Ile His Gly His 435 440 445	1344
ATC AGA GAC AAG GAA GCC CCC CAG AAG AGC TGG GCA CCTTAG Ile Arg Asp Lys Glu Ala Pro Gln Lys Ser Trp Ala 450 455 460	1386

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 460 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Trp Gln Leu Thr Ser Leu Leu Leu Phe Val Ala Thr Trp Gly Ile
 1 5 10 15
 Ser Gly Thr Pro Ala Pro Leu Asp Ser Val Phe Ser Ser Ser Glu Arg
 20 25 30
 Ala His Gln Val Leu Arg Ile Arg Lys Arg Ala Asn Ser Phe Leu Glu
 35 40 45
 Glu Leu Arg His Ser Ser Leu Glu Arg Glu Cys Ile Glu Glu Ile Cys
 50 55 60
 Asp Phe Glu Glu Ala Lys Glu Ile Phe Gln Asn Val Asp Asp Thr Leu
 65 70 75 80
 Ala Phe Trp Ser Lys His Val Asp Gly Asp Gln Cys Leu Val Leu Pro
 85 90 95
 Leu Glu His Pro Cys Ala Ser Leu Cys Cys Gly His Gly Thr Cys Ile
 100 105 110
 Asp Gly Ile Gly Ser Phe Ser Cys Asp Cys Arg Ser Gly Trp Glu Gly
 115 120 125
 Arg Phe Cys Gln Arg Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn
 130 135 140
 Gly Gly Cys Thr His Tyr Cys Leu Glu Glu Val Gly Trp Arg Arg Cys
 145 150 155 160
 Ser Cys Ala Pro Gly Tyr Lys Leu Gly Asp Asp Leu Leu Gln Cys His
 165 170 175
 Pro Ala Val Lys Phe Pro Cys Gly Arg Pro Trp Lys Arg Met Glu Lys
 180 185 190
 Lys Arg Ser His Leu Lys Arg Asp Thr Glu Asp Gln Glu Asp Gln Val
 195 200 205
 Asp Pro Arg Leu Ile Asp Gly Lys Met Thr Arg Arg Gly Asp Ser Pro
 210 215 220

Trp Gln Val Val Leu Leu Asp Ser Lys Lys Lys Leu Ala Cys Gly Ala
225 230 235 240

Val Leu Ile His Pro Ser Trp Val Leu Thr Ala Ala His Cys Met Asp
245 250 255

Glu Ser Lys Lys Leu Leu Val Arg Leu Gly Glu Tyr Asp Leu Arg Arg
260 265 270

Trp Glu Lys Trp Glu Leu Asp Leu Asp Ile Lys Glu Val Phe Val His
275 280 285

Pro Asn Tyr Ser Lys Ser Thr Thr Asp Asn Asp Ile Ala Leu Leu His
290 295 300

Leu Ala Gln Pro Ala Thr Leu Ser Gln Thr Ile Val Pro Ile Cys Leu
305 310 315 320

Pro Asp Ser Gly Leu Ala Glu Arg Glu Leu Asn Gln Ala Gly Gln Glu
325 330 335

Thr Leu Val Thr Gly Trp Gly Tyr His Ser Ser Arg Glu Lys Glu Ala
340 345 350

Lys Arg Asn Arg Thr Phe Val Leu Asn Phe Ile Lys Ile Pro Val Val
355 360 365

Pro His Asn Glu Cys Ser Glu Val Met Ser Asn Met Val Ser Glu Asn
370 375 380

Met Leu Cys Ala Gly Ile Leu Gly Asp Arg Gln Asp Ala Cys Glu Gly
385 390 395 400

Asp Ser Gly Gly Pro Met Val Ala Ser Phe His Gly Thr Trp Phe Leu
405 410 415

Val Gly Leu Val Ser Trp Gly Glu Gly Cys Gly Leu Leu His Asn Tyr
420 425 430

Gly Val Tyr Thr Lys Val Ser Arg Tyr Leu Asp Trp Ile His Gly His
435 440 445

Ile Arg Asp Lys Glu Ala Pro Gln Lys Ser Trp Ala
450 455 460

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10807 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ACGCGTGTCTG ACCTGCAGGT CAACGGATCT CTGTGTCTGT TTTCATGTTA GTACCACACT	60
GTTTTGGTGG CTGTAGCTTT CAGCTACAGT CTGAAGTCAT AAAGCCTGGT ACCTCCAGCT	120
CTGTTCTCTC TCAAGATTGT GTTCTGCTGT TTGGGTCTTT AGTGTCTCCA CACAATTTT	180
AGAATTGTTT GTTCTAGTTC TGTGAAAAAT GATGCTGGTA TTTTGATAAG GATTGCATTG	240
AATCTGTAAA GCTACAGATA TAGTCATTGG GTAGTACAGT CACTTTAACA ATATTAACTC	300
TTCACATCTG TGAGCATGAT ATATTTTCCC CCTCTATATC ATCTTCAATT CCTCCTATCA	360
GTTTCTTTCA TTGCAGTTTT CTGAGTACAG GTCTTACACC TCCTTGGTTA GAGTCATTCC	420
TCAGTATTTT ATTCTTTTGA TACAATTGTG AATGAGGTAA TTTTCTTAGT TTCTCTTTCT	480
GATAGCTCAT TGTTAGTGTA TATATAGAAA AGCAACAGAT TTCTATGTAT TAATTTTGTA	540
TCCTGCAACA GATTTCTATG TATTAATTTT GTATCCTGCT ACTTTACGGA ATTCACCTAT	600
TAGCTTTTTG GTGACATCTT GAGGATTTTC TGAAGAAAAT GGCATGGTAT GGTACGACAA	660
GGTGTCTATG CATCTGCAAA CAGTGGCAGT TTTCCTTCTT CCCTTCCAAC CTGGAATTCT	720
TTGATTTCTT TCTGTCTGAG TACGACTAGG ATTCCCAATA CTATACCGAA TAAAAGTGGC	780
AAGAGTGGAC ATCCTTGTCT TATTTTCTG ACCTTAGAGG AAATGCTTTC AGTTTTCAC	840
CATTAATTAT AATGTTTACT GTGGGCTTGT CATATGTGGC CTTCAATTATA TGAAGTCTA	900
TTCCCTCTAT ACCCACCTTG TTGAGAGTTT TTATCATAAA AGTATGTTGA ATTTGTCAA	960
AAGTTTTTCC TGCATCTATT GAGATGATTT TACTCTTCA ATTCATTAAT GATTTTATT	1020

CTTCATTTTG TTAATGATTT CCATTCTTCA ATTTGTTAAC GTGGTATATC ACATTGATTG	1080
ATTTGTGGAT ACCTTTGTAT CCTGGGATA AACCTCACTT GATCATGAGC TTTCAATGTA	1140
TTTTTGAATT CACTTTGCTA ATATTCTGTT GGGTATTTTT GCATCTCTAT TCATCAATGA	1200
TATTGGCCTA AGAAAGGTTT TGTCTGGTTT TAGTATCAGG GTGATGCTGG CCTCATAGAG	1260
AGAGTTTAGA AGCATTTCCT CCTCTTTGAT TTTTCGGAAT AGTTTGAGTA GGATAGGTAT	1320
TAACTCTTCT TTAAATGTTT GGGGACTTCC CTGGTGAGCC GGTGGTTGAG AATCCGCCTC	1380
AGGGATGTGG GTTTGATCCC TGGTCAGGGA ACCATTAATA AGATCCCACA TGCTGCAGGC	1440
AACAAGCCCC CAAGCTGCAA CCACTGAGCT GCAACCGCTG CAGTGCCAC AGGCCACGAC	1500
CAGAGAAAGC CCACATACAG CAGGGAAGAC CCAGCACAAC CGGAAAAAGG AGTTTGGTGG	1560
AATACAGCTG TGAAGCCGTC TGGTCCTGGA CTCCTGCTTG AGGGAATTTT TAAAAATTA	1620
TTGATTCAAT TTCATTACTG GTAAGTGGTC TGTTTCATATT TTCTATTTCT TCCGGGTTCA	1680
GTCTTGGGAG ATTGTACATG CCTAGGAATG TGTCCGTTTC TTCTAGGTTG TCCATTTTAT	1740
TGGACATGCA TGGGAGCACA CAGCACCGAC CAGCGAGACT CATGCTGGCT TCCTGGGGCC	1800
AGGCTGGGGC CCCAAGCAGC ATGGCATCCT AGAGTGTGTG AAAGCCCACT GACCCTGCCC	1860
AGCCCCACAA TTTCATTCTG AGAAGTGATT CCTTGCTTCT GCACTTACAG GCCCAGGATC	1920
TGACCTGCTT CTGAGGAGCA GGGGTTTTGG CAGGACGGGG AGATGCTGAG AGCCGACGGG	1980
GGTCCAGGTC CCCTCCCAGG CCCCCTGTC TGGGGCAGCC CTTGGGAAAG ATTGCCCCAG	2040
TCTCCCTCCT ACAGTGGTCA GTCCCAGCTG CCCCAGGCCA GAGCTGCTTT ATTTCCGTCT	2100
CTCTCTCTGG ATGGTATTCT CTGGAAGCTG AAGGTTCTCTG AAGTTATGAA TAGCTTTGCC	2160
CTGAAGGGCA TGGTTTGTGG TCACGGTTCA CAGGAACTTG GGAGACCCTG CAGCTCAGAC	2220
GTCCCGAGAT TGGTGGCACC CAGATTTCCT AAGCTCGCTG GGGAACAGGG CGCTTGTTTC	2280
TCCCTGGCTG ACCTCCCTCC TCCCTGCATC ACCCAGTTCT GAAAGCAGAG CGGTGCTGGG	2340

GTCACAGCCT CTCGCATCTA ACGCCGGTGT CCAAACCACC CGTGCTGGTG TTCGEGGGGC	2400
TACCTATGGG GAAGGGCTTC TACTGCAGT GGTGCCCCC GTCCCCTCTG AGATCAGAAG	2460
TCCCAGTCCG GACGTCAAAC AGGCCGAGCT CCCTCCAGAG GCTCCAGGGA GGGATCCTTG	2520
CCCCCCCCGCT GCTGCCTCCA GTCCTGGTG CCGCACCTT GAGCCTGATC TTGTAGACGC	2580
CTCAGTCTAG TCTCTGCCTC CGTGTTACA CGCCTTCTCC CCATGTCCCC TCCGTGTCCC	2640
CGTTTTCTCT CACAAGGACA CCGGACATTA GATTAGCCCC TGTTCAGCC TCACCTGAAC	2700
AGCTCACATC TGTAAGACC TAGATTCAA ACAAGATTCC AACCTGAAGT TCCCGGTGGA	2760
TGTGAGTTCT GGGGCGACAT CCTTCAACCC CATCACAGCT TGCAGTTCAT CGCAACACAT	2820
GGAACCTGGG GTTTATCGTA AAACCCAGGT TCTTCATGAA AACTGAGCT TCGAGTCTTG	2880
TTGCAAGAAT TAAAGGTGCT AATACAGATC AGGGCAAGGA CTGAAGCTGG CTAAGCTCC	2940
TCTTCCATC ACAGGAAAGG GGGGCTGGG GGGGCTGGA GGTCTGCTCC CGTGAGTGAG	3000
CTCTTCTCTG CTACAGTCAC CAACAGTCTC TCTGGGAAGG AAACAGAGG CCAGAGAGCA	3060
AGCCGGAGCT AGTTTAGGAG ACCCCTGAAC CTCCACCAA GATGCTGACC AGCCAGCGGG	3120
CCCCCTGGAA AGACCTACA GTTCAGGGGG GAAGAGGGGC TGACCCGCCA GGTCCCTGCT	3180
ATCAGGAGAC ATCCCCGCTA TCAGGAGATT CCCCACCTT GCTCCCGTTC CCCTATCCCA	3240
ATACGCCAC CCCACCCCTG TGATGAGCAG TTAGTCACT TAGAATGTCA ACTGAAGGCT	3300
TTTGCATCCC CTTTGCCAGA GGCACAAGGC ACCACAGCC TGCTGGGTAC CGACGCCAT	3360
GTGGATTGAG CCAGGAGGCC TGTCCTGCAC CCTCCCTGCT CGGGCCCCCT CTGTGCTCAG	3420
CAACACACCC AGCACCAGCA TTCCCGCTGC TCCTGAGGTC TGCAGGCAGC TCGCTGTAGC	3480
CTGAGCGGTG TGGAGGGAAG TGTCCTGGGA GATTTAAAT GTGAGAGGCG GGAGGTGGGA	3540
GGTTGGGCCC TGTGGGCTG CCCATCCCAC GTGCCTGCAT TAGCCCCAGT GCTGCTCAGC	3600
CGTGCCCCCG CCGCAGGGT CAGGTCACTT TCCCGTCTG GGGTTATTAT GACTCTGTG	3660
ATTGCCATTG CCATTTTGC TACCCTAACT GGGCAGCAGG TGCTTGAGA GCCCTCGATA	3720

CCGACCAGGT CCTCCCTCGG AGCTCGACCT GAACCCCATG TCACCCTTGC CCCAGCCTGC 3780
AGAGGGTGGG TGA CTGCAGA GATCCCTTCA CCCAAGGCCA CGGTCACATG GTTTGGAGGA 3840
GCTGGTGCCC AAGGCAGAGG CCACCCTCCA GGACACACCT GTCCCCAGTG CTGGCTCTGA 3900
CCTGTCTTG TCTAAGAGGC TGACCCCGGA AGTGTTCTTG GCACTGGCAG CCAGCCTGGA 3960
CCCAGAGTCC AGACACCCAC CTGTGCCCCC GCTTCTGGGG TCTACCAGGA ACCGTCTAGG 4020
CCCAGAGGGG ACTTCTGCT TGGCCTTGA TGGAAGAAGG CCTCCTATTG TCCTCGTAGA 4080
GGAAGCCACC CCGGGGCCTG AGGATGAGCC AAGTGGGATT CCGGGAACCG CGTGGCTGGG 4140
GGCCCAGCCC GGGCTGGCTG GCCTGCATGC CTCCTGTATA AGGCCCAAG CCTGCTGTCT 4200
CAGCCCTCCA CTCCCTGCAG AGCTCAGAAG CACGACCCCA GGGATATCCC TGCAGCCATG 4260
AAGTGCTCC TGCTTGCCCT GGGCCTGGCC CTCGCCTGTG GCGTCCAGGC CATCATCGTC 4320
ACCCAGACCA TGAAAGGCCT GGACATCCAG AAGGTTGAG GGTGGCCGG GTGGGTGAGT 4380
TGCAGGGCGG GCAGGGGAGC TGGGCCTCAG AGAGCCAAGA GAGGCTGTGA CGTTGGGTTC 4440
CCATCAGTCA GCTAGGGCCA CCTGACAAAT CCCCCTGGG GCAGCTTCAA CCAGGCGTTC 4500
ACTGTCTTGC ATTCTGGAGG CTGGAAGCCC AAGATCCAGG TGTTGGCAGG GCTGGCTTCT 4560
CCTGCGGCCG CTCTCTGGGG AGCAGACGGC CGTCTTCTCC AGTCCTCTGC GCGCCCTGAT 4620
TTCTCTTCC TGTGAGGCCA CCAGGCCTGC TGGAAACACG CCTGCCTGCG CAGCTTCACA 4680
CGACCTTTGT CATCTCTTA AAGGCCATGT CTCCAGAGTC ATGTGTTGAA GTTCTGGGGG 4740
Ttagtgggac acagttcagc ccctaaaaga gtctctctgc ccctcaaatt ttccccacct 4800
CCAGCCATGT CTCCCCAAGA TCCAAATGTT GCTACATGTG GGGGGGCTCA TCTGGGTCCC 4860
TCTTTGGGT CAGTGTGAGT CTGGGAGAG CATTCCCCAG GGTGCAGAGT TGGGGGGAGT 4920
ATCTCAGGGC TGCCAGGCC GGGGTGGGAC AGAGAGCCCA CTGTGGGGCT GGGGGCCCCT 4980
TCCCACCCCC AGAGTGCAAC TCAAGGTCCC TCTCCAGGTG GCGGGGACTT GGCACCTCTT 5040

GGCTATGGCG GCCAGCGACA TCTCCCTGCT GGATGCCCAG AGTGCCCCC TGAGAGTGTA	5100
CGTGGAGGAG CTGAAGCCCA CCCCCGAGGG CAACCTGGAG ATCCTGCTGC AGAAATGGTG	5160
GGCGTCTCTC CCCAACATGG AACCCCCACT CCCAGGGCT GTGGACCCCC CGGGGGGTGG	5220
GGTGCAGGAG GGACCAGGGC CCCAGGGCTG GGGAAGAGGG CTCAGAGTTT ACTGCTACCC	5280
GGCGCTCCAC CCAAGGCTGC CCACCCAGGG CTTTTTTTTT TTTTAACTT TTATTAATTT	5340
GATGCTTCAG AACATCATCA AACAAATGAA CATAAAACAT TCATTTTTGT TTA CTGGAA	5400
GGGGAGATAA AATCCTCTGA AGTGGAATG CATAGCAAAG ATACATACAA TGAGGCAGGT	5460
ATTCTGAATT CCCTGTTAGT CTGAGGATTA CAAGTGTATT TGAGCAACAG AGAGACATTT	5520
TCATCATTTT TAGTCTGAAC ACCTCAGTAT CTAAAATGAA CAAGAAGTCC TGGAAACGAA	5580
GCAGTGTGGG GATAGGCCCG TGTGAAGGCT GCTGGGAGGC AGCAGACCTG GGTCTTCGGG	5640
CTCAAGCAGT TCCCGTACC AGCCCTGTCC ACCTCAGACG GGGGTCAGGG TGCAGGAGAG	5700
AGCTGGATGG GTGTGGGGGC AGAGATGGGG ACCTGAACCC CAGGGCTGCC TTTTGGGGT	5760
GCCTGTGGTC AAGGCTCTCC CTGACCTTTT CTCTCTGGCT TCATCTGACT TCTCTGGCC	5820
CATCCACCCG GTCCCCTGTG GCCTGAGGTG ACAGTGAGTG CGCCGAGGCT AGTTGACCAG	5880
CTGGCTCCTA TGCCCATGCC ACCCCCCTCC AGCCCTCCTG GGCCAGCTTC TGCCCTGGC	5940
CCTCAGTTCA TCCTGATGAA AATGGTCCAT GCCAATGGCT CAGAAAGCAG CTGCTTTCA	6000
GGGAGAACGG CGAGTGTGCT CAGAAGAAGA TTATTGCAGA AAAAACCAAG ATCCCTGCGG	6060
TGTTCAAGAT CGATGGTGAG TCCGGGTCCC TGGGGGACAC CCACCACCCC CGCCCCGGG	6120
GA CTGTGGAC AGGTT CAGGG GGCTGGCGTC GGGCCCTGGG ATGCTAAGGG ACTGGTGGTG	6180
ATGAAGACAC TGCCCTGACA CCTGCTTCAC TTGCCTCCCC TGCCACCTGC CCGGGGCCCTT	6240
GGGGCGGTGG CCATGGGCAG GTCCCGGCTG GCGGGCTAAC CCACCAGGGT GACACCCGAG	6300
CTCTCTTTGC TGGGGGGCGG GCGGTGCTCT GGGCCCTCAG GCTGAGCTCA GGAGGTACCT	6360
GTGCCCTCCC AGGGGTAACC GAGAGCCGTT GCCCACTCCA GGGGCCCAGG TGCCCCACGA	6420

CCCCAGCCCG CTCCACAGCT CCTTCATCTC CTGGAGACAA ACTCTGTCCG CCCTCGCTCA 6480
TTCATTGTT CGTCCTAAAT CCGAGATGAT AAAGCTTCGA GGGGGGGTTG GGGTTCCATC 6540
AGGGCTGCCC TTCCGCCGGG CAGCCTGGGC CACATCTGCC CTTGGCCCCC TCAGGACTCA 6600
CTCTGACTGG AGGCCCTGCA CTGACTGACG CCAGGGTGCC CAGCCCAGGG TCTCTGGCGC 6660
CATCCAGCTG CACTGGGTTT GGGTGCTGGT CCTGCCCCCA AGCTGCCCGG ACACCACAGG 6720
CAGCCGGGGC TGCCCACTGG CCTCGGTCAG GGTGAGCCCC AGCTGCCCCC GCTCAGGGCT 6780
TGCCCCGACA ATGACCCCAT CCTCAGGACG CACCCCCCTT CCCTTGCTGG GCAGTGTCCA 6840
GCCCCACCCG AGATCGGGGG AAGCCCTATT TCTTGACAAC TCCAGTCCCT GGGGGAGGGG 6900
GCCTCAGACT GAGTGGTGAG TGTTCCCAAG TCCAGGAGGT GGTGGAGGGT CCTGGCGGAT 6960
CCAGAGTTGA CAGTGAGGGC TTCCTGGGCC CCATGCGCCT GGCAGTGGCA GCAGGGAAGA 7020
GGAAGCACCA TTTCAGGGGT GGGGGATGCC AGAGGCGCTC CCCACCCCGT CTTGCGCGGG 7080
TGGTGACCCC GGGGGAGCCC CGCTGGTCGT GGAGGGTGCT GGGGGCTGAC TAGCAACCCC 7140
TCCCCCCCCG TTGGAActCA CTTTTCTCCC GTCTTGACCG CGTCCAGCCT TGAATGAGAA 7200
CAAAGTCCTT GTGCTGGACA CCGACTACAA AAAGTACCTG CTCTTCTGCA TGGAAAACAG 7260
TGCTGAGCCC GAGCAAAGCC TGGCCTGCCA GTGCCTGGGT GGGTGCCAAC CCTGGCTGCC 7320
CAGGGAGACC AGCTGCGTGG TCCTTGCTGC AACAGGGGGT GGGGGGTGGG AGCTTGATCC 7380
CCAGGAGGAG GAGGGGTGGG GGGTCCCTGA GTCCCGCCAG GAGAGAGTGG TCGCATACCG 7440
GGAGCCAGTC TGCTGTGGGC CTGTGGGTGG CTGGGGACGG GGGCCAGACA CACAGGCCGG 7500
GAGACGGGTG GGCTGCAGAA CTGTGACTGG TGTGACCGTC GCGATGGGGC CGGTGGTCAC 7560
TGAATCTAAC AGCCTTTGTT ACCGGGGAGT TTCAATTATT TCCAAAATA AGAACTCAGG 7620
TACAAAGCCA TCTTTCACT ATCACATCCT GAAAACAAAT GGCAGGTGAC ATTTTCTGTG 7680
CCGTAGCAGT CCCACTGGGC ATTTTCAGGG CCCCTGTGCC AGGGGGGCGC GGGCATCGGC 7740

GAGTGGAGGC TCCTGGCTGT GTCAGCCGGC CCAGGGGGAG GAAGGGACCC GGACAGCCAG	7800
AGGTGGGGGG CAGGCTTTCC CCCTGTGACC TGCAGACCCA CTGCACTGCC CTGGCAGGAA	7860
GGGAGGGGAA CTAGGCCAAG GGGGAAGGGC AGGTGCTCTG GAGGGCAAGG GCAGACCTGC	7920
AGACCACCTT GGGGAGCAGG GACTGACCCC CGTCCCTGCC CCATAGTCAG GACCCCGGAG	7980
GTGGACAACG AGGCCCTGGA GAAATTCGAC AAAGCCCTCA AGGCCCTGCC CATGCACATC	8040
CGGCTTGCTT TCAACCCGAC CCAGCTGGAG GGTGAGCACC CAGGCCCCGC CCTTCGCCAG	8100
GGCAGGAGCC ACCCGGCCCC GGGACGACCT CCTCCCATGG TGACCCCCAG CTCCCAGGC	8160
CTCCCAGGAG GAAGGGGTGG GGTGCAGCAC CCCGTGGGGG CCCCCTCCCC ACCCCCTGCC	8220
AGGCCTCTCT TCCCGAGGTG TCCAGTCCCA TCCTGACCCC CCCATGACTC TCCCTCCCCC	8280
ACAGGGCAGT GCCACGTCTA GGTGAGCCCC TGCCGGTGCC TCTGGGGTAA GCTGCCTGCC	8340
CTGCCCCACG TCCTGGGCAC ACACATGGGG TAGGGGGTCT TGGTGGGGCC TGGGACCCCA	8400
CATCAGGCCC TGGGGTCCCC CCTGTGAGAA TGGCTGGAAG CTGGGGTCCC TCCTGGCGAC	8460
TGCAGAGCTG GCTGGCCGCG TGCCACTCTT GTGGGTGACC TGTGTCCTGG CCTCACACAC	8520
TGACCTCCTC CAGCTCCTTC CAGCAGAGCT AAGGCTAAGT GAGCCAGAAT GGTACCTAAG	8580
GGGAGGCTAG CGGTCTTCTT CCCGAGGAGG GGCTGTCCTG GAACCACCAG CCATGGAGAG	8640
GCTGGCAAGG GTCTGGCAGG TGCCCCAGGA ATCACAGGGG GGCCCCATGT CCATTTCAGG	8700
GCCCGGGAGC CTTGGACTCC TCTGGGGACA GACGACGTCA CCACCGCCCC CCCCCATCA	8760
GGGGGACTAG AAGGGACCAG GACTGCAGTC ACCCTTCCTG GGACCCAGGC CCCTCCAGGC	8820
CCCTCCTGGG GCTCCTGCTC TGGGCAGCTT CTCCTTCACC AATAAAGGCA TAAACCTGTG	8880
CTCTCCCTTC TGAGTCTTTG CTGGACGACG GGCAGGGGGT GGAGAAGTGG TGGGGAGGGA	8940
GTCTGGCTCA GAGGATGACA GCGGGGCTGG GATCCAGGGC GTCTGCATCA CAGTCTTGTC	9000
ACAACTGGGG GCCCACACAC ATCACTGCGG CTCTTTGAAA CTTTCAGGAA CCAGGGAGGG	9060
ACTCGGCAGA GACATCTGCC AGTTCACTTG GAGTGTTTCA TCAACACCCA AACTCCACAA	9120

AGGACAGAAA GTGGAAAATG GCTGTCTCTT AGTCTAATAA ATATTGATAT GAAACTCAAG 9180
TTGCTCATGG ATCAATATGC CTTTATGATC CAGCCAGCCA CTA CTGTCGT ATCAACTCAT 9240
GTACCCAAAC GCACTGATCT GTCTGGCTAA TGATGAGAGA TTCCCAGTAG AGAGCTGGCA 9300
AGAGGTCACA GTGAGAACTG TCTGCACACA CAGCAGAGTC CACCAGTCAT CCTAAGGAGA 9360
TCAGTCCTGG TGTTCAATTGG AGGACTGATG TTGAAGCTGA AACTCCAATG CTTTGGCCAC 9420
CTGATGTGAA GAGCTGACTC ATTTGAAAAG ACCCTGATGC TGGGAAAGAT TGAGGGCAGG 9480
AGGAGAAGGG GACGACAGAG GATGAGATGG TTGGATGGCA TCACCAACAC AATGGACATG 9540
GGTTTGGGTG GACTCCAGGA GTTGGTGATG GACAGGGAGG CCTGGCGTGC TACGGAAGCG 9600
GTTTATGGGG TCACAAAGAC TGAGTGACTG AACTGAGCTG AACTGAATGG AAATGAGGTA 9660
TACAGCAAAG TGGGGATTTT TTAGATAATA AGAATATACA CATAACATAG TGTATACTCA 9720
TATTTTTATG CATACTGAA TGCTCAGTCA CTCAGTCGTA TCTGACTCTG TGACCTATGG 9780
ACCGTAGCCT TCCAGGTTTC TTCTGTCCAC AGAATTCTCC AAGGCAAGAA TACTGGAGTG 9840
GGTAGCCATT TCCTCCTCCA GGGGATCCTC CCGACCCAGG GATTGAACCG GCATCTCCTG 9900
TATTGGCAGG TGGATTCTTT ACCACTGTGC CACCAGGGAA GCCCGTGTTA CTCTCTATGT 9960
CCCACTTAAT TACCAAAGCT GCTCCAAGAA AAAGCCCCTG TGCCCTCTGA GCTTCCCGGC 10020
CTGCAGAGGG TGGTGGGGGT AGACTGTGAC CTGGGAACAC CCTCCCGCTT CAGGACTCCC 10080
GGGCCACGTG ACCCACAGTC CTGCAGACAG CCGGGTAGCT CTGCTCTTCA AGGCTCATTA 10140
TCTTTAAAAA AACTGAGGT CTATTTTGTG ACTTCGCTGC CGTAACTTCT GAACATCCAG 10200
TGCGATGGAC AGGACCTCCT CCCAGGCCT CAGGGGCTTC AGGGAGCCAG CCTTCACCTA 10260
TGAGTCACCA GAACTCGGG GGTGGCCCCG CCTTCAGGGT GCTCACAGTC TTCCCATCGT 10320
CCTGATCAAA GAGCAAGACC AATGACTTCT TAGGAGCAAG CAGACACCCA CAGGACACTG 10380
AGGTTACCA GAGCTGAGCT GTCCTTTTGA ACCTAAAGAC ACACAGCTCT CGAAGGTTTT 10440

CTCTTTAATC TGGATTTAAG GCCTACTTGC CCCTCAAGAG GGAAGACAGT CCTGCATGTC 10500
CCCAGGACAG CCACTCGGTG GCATCCGAGG CCACTTAGTA TTATCTGACC GCACCCCTGGA 10560
ATTAATCGGT CCAAACCTGGA CAAAAACCTT GGTGGGAAGT TTCATCCCAG AGGCCCTCAAC 10620
CATCCTGCTT TGACCACCCT GCATCTTTTT TTCTTTTATG TGTATGCATG TATAATATA 10680
TATATATTTT TTTTTTTTTC ATTTTTTGGC TGTGCTGGCT GTTCGTTGCA GTTCGGTGCG 10740
CAGGCTTCTC TCTAGTTTCT CTCTAGTCTT CTCTTATCAC AGAGCAGTCT CTAGACGATC 10800
GACGCGT 10807

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AATTCGATC GACGCGTCGA CGATATACTC TAGACGATCG ACGCGTA 47

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGCTACGCG TCGATCGTCT AGAGTATATC GTCGACGCGT CGATCGG 47

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGGATCCCCT GCCGGTGCCT CTGG

24

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AACGCGTCAT CCTCTGTGAG CCAG

24

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC6839

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ACTACGTAGT

10

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC962

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGTCACCTGA GAAGAAAACG AGACA

25

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6303

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATTTGCGGCC GCCTGCAGCC ATGTGGCAGC TCACAAGCCT CCTGC

45

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6337

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAGGAAGGAG TTGGCGCGCT TCGCCGTTG CAGCACCTGG TGGGC

45

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC6306

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CTTCTTCCTG AATTCTGTTT CTTCG

25

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC6338

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGGATCCGCA AGCGCGCCAA CTCCTTCC

28

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC6373

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

AAAGTAAAAA AAGATCTAAA AATTTAAC

28

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC6305

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTGTCTCGTT TTCTTCTTAA GTGACTGCGC TT

32

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: ZC6302

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TTAAGAAGAA AACGAGACAC AGAAGACCAA GAAGACCAAG TAGATCCGC

49

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: ZC6304

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGATCTACTT GGTCTTCTTG GTCTTCTGTG TCTCGTTTTC TTC

43

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Arg Arg Lys Arg
1

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Lys Arg Lys Arg
1

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ser His Leu Arg Arg Lys Arg Asp
 1 5

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6763 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

ACGCGTCGAC CTGCAGGTCA ACGGATCTCT GTGTCTGTTT TCATGTTAGT ACCACACTGT	60
TTTGGTGGCT GTAGCTTTCA GCTACAGTCT GAAGTCATAA AGCCTGGTAC CTCCAGCTCT	120
GTTCTCTCTC AAGATTGTGT TCTGCTGTTT GGGTCTTTAG TGTCTCCACA CAATT TTAG	180
AATTGTTTGT TCTAGTTCTG TGAAAAATGA TGCTGGTATT TTGATAAGGA TTGCA TGAA	240
TCTGTAAAGC TACAGATATA GTCATTGGGT AGTACAGTCA CTTTAACAAT ATTAACCTCTT	300
CACATCTGTG AGCATGATAT ATTTTCCCCC TCTATATCAT CTTCAATTCC TCCTA CAGT	360
TTCTTTTCATT GCAGTTTTCT GAGTACAGGT CTTACACCTC CTTGGTTAGA GTCAT CCTC	420
AGTATTTTAT TCCTTTGATA CAATTGTGAA TGAGGTAATT TTCTTAGTTT CTCTT CTGA	480
TAGCTCATTG TTAGTGTATA TATAGAAAAG CAACAGATTT CTATGTATTA ATTTTGTATC	540

CTGCAACAGA TTTCTATGTA TTAATTTTGT ATCCTGCTAC TTTACGGAAT TCACTTATTA	600
GCTTTTTGGT GACATCTTGA GGATTTTCTG AAGAAAATGG CATGGTATGG TAGGACAAGG	660
TGTCATGTCA TCTGCAAACA GTGGCAGTTT TCCTTCTTCC CTCCAACCT GGATTTCTTT	720
GATTTCTTTC TGTCTGAGTA CGACTAGGAT TCCAATACT ATACCGAATA AAAGTGCGAA	780
GAGTGGACAT CCTTGTCTTA TTTTCTGAC CTTAGAGGAA ATGCTTTCAG TTTTTCACCA	840
TTAATTATAA TGTTTACTGT GGGCTTGTCA TATGTGGCCT TCATTATATG GAGGTCTATT	900
CCCTCTATAC CCACCTTGTT GAGAGTTTTT ATCATAAAAG TATGTIGAAT TTTGTCAAAA	960
GTTTTTCCTG CATCTATTGA GATGATTTTT ACTCTTCAAT TCATTAATGA TTTTATTCT	1020
TCATTTTGTT AATGATTTC ATTCTTCAAT TTGTAACTG GGTATATCAC ATTGATTGAT	1080
TTGTGGATAC CTTTGTATCC CTGGGATAAA CCTCACTTGA TCATGAGCTT TCAATGTATT	1140
TTGAATTCA CTTTGCTAAT ATTCTGTTGG GTATTTTTC ATCTCTATTC ATCAATGATA	1200
TTGGCCTAAG AAAGGTTTTG TCTGGTTTTA GTATCAGGGT GATGCTGGCC TCATAGAGAG	1260
AGTTTAGAAG CATTTCTCC TCTTTGATTT TTCGGAATAG TTTGAGTAGG ATAGGTATTA	1320
ACTCTTCTTT AAATGTTTGG GGACTTCCCT GGTGAGCCGG TGGTTGAGAA TCCGCCTCAG	1380
GGATGTGGGT TTGATCCCTG GTCAGGGAAC CATTAATAAG ATCCCACATG CTGCAGGCAA	1440
CAAGCCCCCA AGCTGCAACC ACTGAGCTGC AACCGCTGCA GTGCCCACAG GCCACGACCA	1500
GAGAAAGCCC ACATACAGCA GGAAGACCC AGCACAACCG GAAAAGGAG TTTGGTGGAA	1560
TACAGCTGTG AAGCCGTCTG GTCCTGGACT CCTGCTTGAG GGAATTTTTT AAAAATTATT	1620
GATTCAATTT CATTACTGGT AACTGGTCTG TTCATATTTT CTATTCTTC CGGGTTCAGT	1680
CTTGGGAGAT TGTACATGCC TAGGAATGTG TCCGTTTCTT CTAGGTTGTC CATTTTATTG	1740
GACATGCATG GGAGCACACA GCACCGACCA GCGAGACTCA TGCTGGCTTC CTGGGGCCAG	1800
GCTGGGGCCC CAAGCAGCAT GGCATCCTAG AGTGTGTGAA AGCCCACTGA CCCTGCCCAG	1860
CCCCACAATT TCATTCTGAG AAGTGATTCC TTGCTTCTGC ACTTACAGGC CCAGGATCTG	1920

ACCTGCTTCT GAGGAGCAGG GGTTTTGGCA GGACGGGGAG ATGCTGAGAG CCGACGGGGG 1980
TCCAGGTCCC CTCCCAGGCC CCCCTGTCTG GGGCAGCCCT TGGGAAAGAT TGCCCCAGTC 2040
TCCCTCCTAC AGTGGTCAGT CCCAGCTGCC CCAGGCCAGA GCTGCTTTAT TTCCGTCTCT 2100
CTCTCTGGAT GGTATTCTCT GGAAGCTGAA GGTTCTGAA GTTATGAATA GCTTTGCCCT 2160
GAAGGGCATG GTTTGTGGTC ACGGTTTACA GGAACCTGGG AGACCCTGCA GCTCAGACGT 2220
CCCGAGATTG GTGGCACCCA GATTTCTTAA GCTCGCTGGG GAACAGGGCG CTTGTTCTC 2280
CCTGGCTGAC CTCCCTCCTC CCTGCATCAC CCAGTTCTGA AAGCAGAGCG GTGCTGGGGT 2340
CACAGCCTCT CGCATCTAAC GCCGGTGTCC AAACCACCCG TGCTGGTGTT CGGGGGGCTA 2400
CCTATGGGGA AGGGCTTCTC ACTGCAGTGG TGCCCCCGT CCCCTCTGAG ATCAGAAAGTC 2460
CCAGTCCGGA CGTCAAACAG GCCGAGCTCC CTCCAGAGGC TCCAGGGAGG GATCCTTGCC 2520
CCCCCGCTGC TGCCTCCAGC TCCTGGTGCC GCACCCTTGA GCCTGATCTT GTAGACGCCT 2580
CAGTCTAGTC TCTGCCTCCG TGTTACACG CCTTCTCCCC ATGTCCCCTC CGTGTCCTCCG 2640
TTTTCTCTCA CAAGGACACC GGACATTAGA TTAGCCCCTG TTCCAGCCTC ACCTAACAG 2700
CTCACATCTG TAAAGACCTA GATTCCAAAC AAGATTCCAA CCTGAAGTTC CCGGTGGATG 2760
TGAGTTCTGG GGCACATCC TTCAACCCCA TCACAGCTTG CAGTTCATCG CAAAACATGG 2820
AACCTGGGGT TTATCGTAAA ACCCAGGTTC TTCATGAAAC ACTGAGCTTC GAGGCTTGTT 2880
GCAAGAATTA AAGGTGCTAA TACAGATCAG GGCAAGGACT GAAGCTGGCT AAGCCTCCTC 2940
TTTCCATCAC AGGAAAGGGG GGCCTGGGGG CGGCTGGAGG TCTGCTCCCG TGAGTGAGCT 3000
CTTTCCTGCT ACAGTCACCA ACAGTCTCTC TGGGAAGGAA ACCAGAGGCC AGAGAGCAAG 3060
CCGGAGCTAG TTTAGGAGAC CCCTGAACCT CCACCCAAGA TGCTGACCAG CCAGCAGGCC 3120
CCCTGGAAAG ACCCTACAGT TCAGGGGGGA AGAGGGGCTG ACCCGCCAGG TCCCTGCTAT 3180
CAGGAGACAT CCCCCTATC AGGAGATTCC CCCACCTTGC TCCCGTTCCC CTATCCAAT 3240

ACGCCCACCC CACCCCTGTG ATGAGCAGTT TAGTCACTTA GAATGTCAAC TGAAGGCTTT	3300
TGCATCCCCT TTGCCAGAGG CACAAGGCAC CCACAGCCTG CTGGGTACCG ACGCCCATGT	3360
GGATTCAGCC AGGAGGCCTG TCCTGCACCC TCCCTGCTCG GGCCCCCTCT GTGCTCAGCA	3420
ACACACCCAG CACCAGCATT CCCGCTGCTC CTGAGGTCTG CAGGCAGCTC GCTGTAGCCT	3480
GAGCGGTGTG GAGGGAAGTG TCCTGGGAGA TTTAAATGT GAGAGGCGGG AGGTGGGAGG	3540
TTGGGCCCTG TGGGCCTGCC CATCCCACGT GCCTGCATTA GCCCCAGTGC TGCTCAGCCG	3600
TGCCCCCGCC GCAGGGGTCA GGTCACTTTC CCGTCCTGGG GTTATTATGA CTCTTGTCAT	3660
TGCCATTGCC ATTTTGTGCTA CCCTAACTGG GCAGCAGGTG CTTGCAGAGC CCTCGATACC	3720
GACCAGGTCC TCCCTCGGAG CTCGACCTGA ACCCATGTC ACCCTTGCCC CAGCCTGCAG	3780
AGGGTGGGTG ACTGCAGAGA TCCCTTCACC CAAGGCCACG GTCACATGGT TTGGAGGAGC	3840
TGGTGCCCAA GGCAGAGGCC ACCCTCCAGG ACACACCTGT CCCCAGTGCT GGCTCTGACC	3900
TGTCCTTGTC TAAGAGGCTG ACCCCGGAAG TGTTCTTGGC ACTGGCAGCC AGCCTGGACC	3960
CAGAGTCCAG ACACCCACCT GTGCCCCCGC TTCTGGGGTC TACCAGGAAC CGTCTAGGCC	4020
CAGAGGGGAC TTCCTGCTTG GCCTTGGATG GAAGAAGGCC TCCTATTGTC CTCGTAGAGG	4080
AAGCCACCCC GGGGCCTGAG GATGAGCCAA GTGGGATTCC GGGAAACCGC TGGCTGGGGG	4140
CCCAGCCCGG GCTGGCTGGC CTGCATGCCT CCTGTATAAG GCCCCAAGCC TGCTGTCTCA	4200
GCCCTCCACT CCCTGCAGAG CTCAGAAGCA CGACCCCAGG GATATCATCG ATAAGCTTGG	4260
ATCCCCTGCC GGTGCCTCTG GGGTAAGCTG CCTGCCCTGC CCCACGTCCT GGGCACACAC	4320
ATGGGGTAGG GGGTCTTGGT GGGGCCTGGG ACCCCACATC AGGCCCTGGG GTCCCCCCTG	4380
TGAGAATGGC TGGAAGCTGG GGTCCCTCCT GGCGACTGCA GAGCTGGCTG GCCGCGTGCC	4440
ACTCTTGTTG GTGACCTGTG TCCTGGCCTC ACACACTGAC CTCCTCCAGC TCCTTCCAGC	4500
AGAGCTAAGG CTAAGTGAGC CAGAATGGTA CCTAAGGGGA GGCTAGCGGT CCTTCTCCCG	4560
AGGAGGGGCT GTCCTGGAAC CACCAGCCAT GGAGAGGCTG GCAAGGGTCT GGCAGGTGCC	4620

CCAGGAATCA CAGGGGGGCC CCATGTCCAT TTCAGGGCCC GGGAGCCTTG GACTCCTCTG	4680
GGGACAGACG ACGTCACCAC CGCCCCCCCC CCATCAGGGG GACTAGAAGG GACCAGGACT	4740
GCAGTCACCC TTCCTGGGAC CCAGGCCCCT CCAGGCCCCT CCTGGGGCTC CTGCTCTGGG	4800
CAGCTTCTCC TTCACCAATA AAGGCATAAA CCTGTGCTCT CCCTTCTGAG TCTTCTGCTG	4860
ACGACGGGCA GGGGGTGGAG AAGTGGTGGG GAGGGAGTCT GGCTCAGAGG ATGACAGCGG	4920
GGCTGGGATC CAGGGCGTCT GCATCACAGT CTTGTGACAA CTGGGGGCCC ACACACATCA	4980
CTGCGGCTCT TTGAACTTT CAGGAACCAG GGAGGGACTC GGCAGAGACA TCTGCCAGTT	5040
CACTTGGAGT GTTCAGTCAA CACCCAACT CGACAAAGGA CAGAAAGTGG AAAAAGGCTG	5100
TCTCTTAGTC TAATAAATAT TGATATGAAA CTCAAGTTGC TCATGGATCA ATATGCCTTT	5160
ATGATCCAGC CAGCCACTAC TGTCGTATCA ACTCATGTAC CCAAACGCAC TGATCTGTCT	5220
GGCTAATGAT GAGAGATTCC CAGTAGAGAG CTGGCAAGAG GTCACAGTGA GAACGTCTG	5280
CACACACAGC AGAGTCCACC AGTCATCCTA AGGAGATCAG TCCTGGTGTT CATTGGAGGA	5340
CTGATGTTGA AGCTGAACT CCAATGCTTT GGCCACCTGA TGTGAAGAGC TGACTCATTT	5400
GAAAAGACCC TGATGCTGGG AAAGATTGAG GGCAGGAGGA GAAGGGGACG ACAGAGGATG	5460
AGATGGTTGG ATGGCATCAC CAACACAATG GACATGGGTT TGGGTGGACT CCAGGAGTTG	5520
GTGATGGACA GGGAGGCCTG GCGTGCTACG GAAGCGGTTT ATGGGGTCAC AAAGACTGAG	5580
TGACTGAACT GAGCTGAACT GAATGGAAAT GAGGTATACA GCAAAGTGGG GATTCTTTAG	5640
ATAATAAGAA TATACACATA ACATAGTGTA TACTCATATT TTTATGCATA CCTGAATGCT	5700
CAGTCACTCA GTCGTATCTG ACTCTGTGAC CTATGGACCG TAGCCTTCCA GGTTCTTCT	5760
GTCCACAGAA TTCTCCAAGG CAAGAATACT GGAGTGGGTA GCCATTTCTT CCTCCAGGGG	5820
ATCCTCCCGA CCCAGGGATT GAACCGGCAT CTCCTGTATT GGCAGGTGGA TTCTTTACCA	5880
CTGTGCCACC AGGGAAGCCC GTGTTACTCT CTATGTCCCA CTTAATTACC AAAGCTGCTC	5940

CAAGAAAAAG CCCCTGTGCC CTCTGAGCTT CCCGGCCTGC AGAGGGTGGT GGGGGTAGAC 6000
 TGTGACCTGG GAACACCCTC CCGCTTCAGG ACTCCCGGGC CACGTGACCC ACAGTCCTGC 6060
 AGACAGCCGG GTAGCTCTGC TCTTCAAGGC TCATTATCTT TAAAAAAAC TGAGGTCTAT 6120
 TTTGTGACTT CGCTGCCGTA ACTTCTGAAC ATCCAGTGCG ATGGACAGGA CCTCCTCCCC 6180
 AGGCCTCAGG GGCTTCAGGG AGCCAGCCTT CACCTATGAG TCACCAGACA CTCGGGGGTG 6240
 GCCCCGCCTT CAGGGTGCTC ACAGTCTTCC CATCGTCCTG ATCAAAGAGC AAGACCAATG 6300
 ACTTCTTAGG AGCAAGCAGA CACCCACAGG AACTGAGGT TCACCAGAGC TGAGCTGTCC 6360
 TTTTGAACCT AAAGACACAC AGCTCTCGAA GGTTTTCTCT TTAATCTGGA TTAAAGGCCT 6420
 ACTTGCCCCCT CAAGAGGGAA GACAGTCCTG CATGTCCCCA GGACAGCCAC TCGGTGGCAT 6480
 CCGAGGCCAC TTAGTATTAT CTGACCGCAC CCTGGAATTA ATCGGTCCAA ACTGGACAAA 6540
 AACCTTGGTG GGAAGTTTCA TCCCAGAGGC CTCAACCATC CTGCTTTGAC CACCCTGCAT 6600
 CTTTTTTTCT TTTATGTGTA TGCATGTATA TATATATATA TATTTTTTTT TTTTTCATT 6660
 TTTGGCTGTG CTGGCTGTTT GTTGCAAGTC GGTGCGCAGG CTTCTCTCTA GTTCTCTCT 6720
 AGTCTTCTCT TATCACAGAG CAGTCTCTAG ACGATCGACG CGT 6763

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Arg Ile Arg Lys Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Gln	Arg	Arg	Lys	Arg
1			5	

CLAIMS

1. A method for producing protein C in a transgenic animal comprising:

providing a DNA construct comprising a first DNA segment encoding a secretion signal and a protein C propeptide operably linked to a second DNA segment encoding protein C, wherein the encoded protein C comprises a two-chain cleavage site modified from Lysine (Lys)-Arginine (Arg) to R₁-R₂-R₃-R₄, and wherein each of R₁, R₂, R₃, R₄ is individually Lys or Arg, and wherein said first and second segments are operably linked to additional DNA segments required for expression of the protein C DNA in a mammary gland of a host female animal;

introducing said DNA construct into a fertilized egg of a non-human mammalian species;

inserting said egg into an oviduct or uterus of a female of said species to obtain offspring carrying said DNA construct;

breeding said offspring to produce female progeny that express said first and second DNA segments and produce milk containing protein C encoded by said second segment, wherein said protein has anticoagulant activity upon activation;

collecting milk from said female progeny; and
recovering the protein C from the milk.

2. The method of claim 1, further comprising the step of activating the protein C.

3. The method of claim 1, wherein R₁-R₂-R₃-R₄ is Arg-Arg-Lys-Arg (SEQ ID NO: 20).

4. The method of claim 1, wherein said species is selected from sheep, rabbits, cattle and goats.

5. The method of claim 1, wherein each of said first and second DNA segments comprises an intron.

6. The method of claim 1, wherein the second DNA segment comprises a DNA sequence of nucleotides as shown in Seq. ID NO: 1 or Seq. ID. NO: 3.

7. The method of claim 6, wherein the second DNA segment comprises the DNA sequence of nucleotides as shown in SEQ. ID. NO: 1.

8. The method of claim 1, wherein the additional DNA segments comprise a transcriptional promoter selected from the group consisting of casein, β -lactoglobulin, α -lactalbumin and whey acidic protein gene promoters.

9. The method of claim 8, wherein the transcriptional promoter is the β -lactoglobulin gene promoter.

10. A transgenic non-human female mammal that produces recoverable amounts of human protein C in its milk, wherein at least 90% of the human protein C in the milk is two-chain protein C.

11. A process for producing a transgenic offspring of a mammal comprising:

providing a DNA construct comprising a first DNA segment encoding a secretion signal and a protein C propeptide operably linked to a second DNA segment encoding protein C, wherein the encoded protein C comprises a two-chain cleavage site modified from Lys-Arg to R_1 - R_2 - R_3 - R_4 , and wherein each of R_1 , R_2 , R_3 , R_4 , is individually Lys or Arg, and wherein said first and second segments are operably linked to additional DNA segments required for expression of the protein C DNA in the mammary gland of a host female animal;

introducing said DNA construct into a fertilized egg of a non-human mammalian species; and

inserting said egg into an oviduct or uterus of a female of said species to obtain offspring carrying said DNA construct.

12. The process according to claim 11, wherein R_1 - R_2 - R_3 - R_4 is Arg-Arg-Lys-Arg (SEQ ID NO: 20).

13. The process according to claim 11, wherein the offspring is female.

14. The process according to claim 11, wherein the offspring is male.

15. A non-human mammal produced according to the process of claim 10.

16. A non-human mammal of claim 15, wherein the mammal is female.

17. A female mammal according to claim 16 that produces milk containing protein C encoded by said DNA construct, wherein said protein C has anticoagulant activity upon activation.

18. A non-human mammalian embryo containing in its nucleus a heterologous DNA segment encoding protein C, wherein the encoded protein C comprises a two-chain cleavage site modified from Lys-Arg to R_1 - R_2 - R_3 - R_4 , and wherein each of R_1 , R_2 , R_3 , R_4 , is individually Lys or Arg.




Fig. 1

2/5




Fig. 2a

3/5




Fig. 2b

4/5




Fig. 2c




Fig. 3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/00 C12N9/64 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC:

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>TRANSGENIC RESEARCH, vol. 3, 1994, pages 355-364, XP000647718 W. DROHAN ET AL: "Inefficient processing of human protein C in the mouse mammary gland" cited in the application see the whole document especially page 362, right column, lines 11-19</p> <p style="text-align: center;">--- -/-</p>	1-18

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

25 March 1997

Date of mailing of the international search report

02. 04. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Van der Schaal, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MIAMI BIO/TECHNOLOGY WINTER SYMPOSIUM ON ADVANCES IN GENE TECHNOLOGY: PROTEIN ENGINEERING AND STRUCTURAL BIOLOGY, MIAMI, FLORIDA, USA, FEBRUARY 4-9, 1995. PROTEIN ENGINEERING 8 (SUPPL.). 1995. 107. ISSN: 0269-2139, XP002028254</p> <p>COLMAN A ET AL: "The transgenic mammary gland as a bioreactor: Expectations and realisations."</p> <p>see page 107, left-hand column, paragraph 5</p> <p>last lines</p> <p>---</p>	1-18
Y	<p>BIOCHEMISTRY,</p> <p>vol. 29, 1990,</p> <p>pages 347-354, XP002028255</p> <p>D. FOSTER ET AL: "Endoproteolytic processing of the dibasic cleavage site in the human protein C precursor in transfected mammalia cells: Effects of sequence alterations on efficiency of cleavage"</p> <p>see the whole document</p> <p>---</p>	1-18
Y	<p>EP 0 319 312 A (LILLY CO ELI) 7 June 1989</p> <p>see the whole document</p> <p>---</p>	1-18
Y	<p>WO 88 00239 A (PHARMACEUTICAL PROTEINS LTD) 14 January 1988</p> <p>cited in the application</p> <p>see the whole document</p> <p>---</p>	4,8,9
Y	<p>WO 92 11757 A (AMERICAN NAT RED CROSS) 23 July 1992</p> <p>see the whole document</p> <p>especially page 11 and 12</p> <p>---</p>	1-18
P,A	<p>WO 96 34966 A (AMERICAN NAT RED CROSS) 7 November 1996</p> <p>-----</p>	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0319312 A	07-06-89	US 4992373 A	12-02-91
		AU 2650988 A	08-06-89
		CN 1035527 A	13-09-89
		DE 3885419 D	09-12-93
		DE 3885419 T	31-03-94
		ES 2059538 T	16-11-94
		HU 209587 B	29-08-94
		IE 61627 B	16-11-94
		IL 88559 A	27-02-94
		JP 2002372 A	08-01-90
		PT 89135 B	29-04-94
		SU 1830081 A	23-07-93
WO 8800239 A	14-01-88	AU 605497 B	17-01-91
		AU 7649087 A	29-01-88
		EP 0274489 A	20-07-88
		JP 1500162 T	26-01-89
		US 5366894 A	22-11-94
		US 5322775 A	21-06-94
		US 5476995 A	19-12-95
WO 9211757 A	23-07-92	AU 1228592 A	17-08-92
		EP 0591219 A	13-04-94
		JP 6507307 T	25-08-94
		US 5589604 A	31-12-96
WO 9634966 A	07-11-96	AU 6347496 A	21-11-96

THIS PAGE BLANK (USPTO)